Acute Inflammation and Brief Symptoms
Mechanisms: Experimentally Induced Allergic Reactions
Clinical Consequences and Treatment
Site of the Inflammation in Asthma
Cell Survival in Airway Tissues
Characteristics of Chronic Inflammation
Chronic Inflammation in the Different Forms of Asthma
Treatment of Exacerbations
Onset and Duration of Treatment
Remodeling of the Airways
Characteristics of Airways Remodeling in Asthma
Treatment and Prevention of Airways Remodeling
Several definitions of asthma have been proposed since the Ciba Foundation Symposium held in 1959 (1). The Global Strategy for Asthma Management and Prevention Report (2) stated that the definition of asthma may be based on pathology and its functional consequences, i.e., “Asthma is a chronic inflammatory disease of the airways in which many cell types play a role, in particular mast cells, eosinophils and T lymphocytes. In susceptible individuals the inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough particularly at night and/or early morning. These symptoms are usually associated with widespread but variable airflow obstruction that is at least partly reversible either spontaneously or with treatment. The inflammation also causes an associated increase in airway responsiveness to a variety of stimuli.” The definition is still imperfect because some patients with asthma show poor reversibility, whereas some chronic bronchitics have an apparent reversibility of their airflow obstruction, which recently has been linked to features of asthma (3).
For many years, the basic alterations of asthma were considered to be bronchospasm, edema, and hypersecretion. Evidence of bronchial inflammation arose from the studies of nonspecific bronchial hyperresponsiveness, bronchoalveolar lavage (BAL) (4), bronchial biopsies (5), and induced sputum (6) and observations made postmortem of patients with asthma who died from an attack of asthma (Figures 1 and 2) or from other causes (5, 7).
The genetic predisposition to develop asthma is now well recognized (8) and the IgE-mediated response to common allergens represents the most common form of the disease in childhood and early adulthood (9). However, even in nonallergic asthma, an immunologic basis for the condition may be considered because the pathological features and the nature of inflammation are largely similar (10, 11) as are high-affinity IgE receptor (Fcɛ RI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma (12).
The treatment of asthma is internationally agreed upon and guidelines have been developed for the management of asthma (2, 13, 14). All guidelines focus on the treatment of inflammation although there are differences between them. Management should take into account that asthma is a condition associated with the following: acute symptoms that can be quickly reversed by bronchodilators; exacerbations caused by chronic inflammation which can be prevented or more slowly reversed by anti-inflammatory drugs; and the process of airway wall remodeling, for which there is no defined treatment yet fully validated. Thus, asthma should be seen as a continuum from symptoms to airway wall remodeling, but the sequence and/or the severity of these events is highly variable from patient to patient.
This report describes the acute inflammation of asthma and its symptoms; the nature of chronic inflammation, its consequences, and how it might be controlled; and the remodeling process, for which less is currently known, and possibilities for altering the process and its reversal.
Precipitous symptomatic attacks of asthma may be caused by several known or unknown factors such as exposure to allergens (9), viruses (15), or indoor and outdoor pollutants (16) and each may induce an acute inflammatory response.
Inhaled allergen challenge may be used as a model to understand acute inflammation in asthma.
Early-phase reaction. Inhaled allergen challenge in allergic patients leads to an early allergic inflammatory allergic reaction and in some cases, this may be followed by a late-phase reaction. The early-phase reaction is initiated after the activation of cells bearing allergen-specific IgE. It is characterized by the rapid activation of airway mast cells (Figure 3) (17, 18) and macrophages (19, 20). Cell types other than basophils and mast cells that bear the high-affinity IgE receptor Fcɛ RI (21) may also participate, but it is not known whether they can be activated directly by allergens. The activated cells rapidly release proinflammatory mediators such as histamine (22), eicosanoids (23), and reactive oxygen species which induce contraction of airways smooth muscle, mucous secretion, and vasodilatation. The bronchial microcirculation has a central role in this inflammatory process (24). Inflammatory mediators induce microvascular leakage with exudation of plasma into the airways (25, 26). Acute plasma protein leakage induces a thickened engorged and edematous airway wall and a resultant narrowing of the airway lumen. In addition, plasma may also traverse the epithelium, pass through the tight junctions, and collect in the airway lumen. Plasma exudation may compromise epithelial integrity, and its presence in the lumen may reduce clearance of mucus (27). Plasma proteins may also promote the formation of viscid luminal plugs of exudate mixed with mucus and inflammatory and epithelial cells. Together, these effects contribute to airflow obstruction.
Late-phase reaction: Cellular events and release of proinflammatory mediators. The late-phase inflammatory reaction occurs between 6 to 9 h after allergen provocation and involves the recruitment and activation of eosinophils (28), CD4+ T cells (29), basophils (30), neutrophils (31, 32), and macrophages (33) (Figure 4). There is selective retention of airway T cells (34), the expression of adhesion molecules (35-37), and the release of selected proinflammatory mediators (18, 38) and cytokines involved in the recruitment and activation of inflammatory cells (22, 39). The activation of T cells after allergen challenge leads to the release of T helper cell, type 2 (Th2)-like cytokines which may be a key mechanism of the late-phase response (40), but it is unlikely that there is sufficient time within the first phase of the late-phase reaction (2 to 4 h) for allergen to stimulate cytokine gene transcription, translation, and protein production in sensitized T cells. However, the release of preformed cytokines by mast cells is the likely initial trigger for the early recruitment of cells (41). This cell type may recruit and induce the more persistent involvement by T cells. Twenty-four hours after allergen challenge, an increase of activated interleukin-2 (IL-2)-positive T cells and of interleukin-5 (IL-5) or granulocyte–macrophage conony–stimulating factor (GM-CSF) messenger RNA (mRNA) expression are observed in bronchial biopsies (42), suggesting the involvement of T cells, possibly in the more chronic phase of the response.
The enhancement of nonspecific bronchial hyperresponsiveness can usually be demonstrated after the late-phase reaction but not after the early-phase reaction following allergen or occupational challenge (43, 44).
Recruitment of inflammatory cells into the airways. The late-phase reaction is considered to be a model system to study the mechanisms of the chronic inflammation of asthma (45, 46). Inflammatory cells mature and are released by bone marrow and traffic in the circulation before being recruited into the airway wall. However, hematopoietic cells are also present in the airways (47). Asthma is associated with increased levels of hemopoietic progenitor cells in bone marrow (48, 49). Cell recruitment rather than replication of preexisting inflammatory cell precursors appears to be the predominant means (Figure 5) but the precise mechanisms are still not clearly defined, and a tissue-directed component may also be underestimated (50).
The recruitment of peripheral blood cells including eosinophils, lymphocytes, and monocytes into inflamed airways is the result of adhesive interactions between circulating inflammatory and microvascular endothelial cells via the production of proinflammatory mediators, cytokines, and chemokines, and the expression of cell surface adhesion molecules. Upregulation of distinct adhesion molecules such as CD11a, CD11b, CD18, or Very Late Antigen (VLA-4) on blood cells and intercellular adhesion molecule-1 (ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells is a critical step for the induction of the inflammatory response (36, 51, 52). The ligand VLA-4 is not present on neutrophils (53), which may, in part, explain the selective recruitment of eosinophils in asthma (54). An increase of such airway vascular adhesion molecules has been observed in asthma (55, 56).
Recruitment of cells into the airways wall is associated with their priming and activation (57) and is also dependent on cytokines such as IL-5 (58) and GM-CSF acting to enhance eosinophil recruitment, terminal maturation (59), and expression of their adhesion molecules (53, 60). Chemokines such as RANTES (regulated upon activation, normal T-cell expressed and secreted) (61, 62) and eotaxin (63, 64) also act on eosinophils and T cells (65) to enhance markedly their recruitment and possibly their activation. RANTES (66) and IL-16, a lymphocyte chemoattractant factor, and macrophage inflammatory protein 1α (MIP-1α) are found in BAL fluid (BALF) of antigen-challenged asthmatics (67) and may also participate in the process.
This bronchoconstrictive response associated with acute inflammation is characterized by brief symptoms including wheezing, dyspnea, and shortness of breath which usually do not persist for more than a day or so.
Prevention of these brief symptoms can be achieved by long-acting β2-agonists (71) such as salmeterol (71, 72) or formoterol (73). There are phenotypic allelic variations in the structure of the β2-adrenergic receptor expressed in lung cells (74) which may be an important factor in the ultimate physiologic response to β2-agonists (75).
Airways inflammation has been widely demonstrated in all forms of asthma, and an association between the extent of inflammation and the clinical severity of asthma has been demonstrated in some (76, 77) but not all studies (78).
The whole mucosal immune system appears to be involved in bronchial asthma. Although devoid of gastrointestinal symptoms, asthmatics and asymptomatic allergic individuals have duodenal pathologic abnormalities mimicking those observed in the bronchial mucosa (79). The reasons for the preferential involvement of the airways in asthma are not known but may be related to the route and dose of allergen exposure or early injury to the airways.
In the bronchial tree, the major site of the airways inflammation is still controversial. It is accepted that both central and peripheral airways are inflamed, but a recent paper has focused on the importance of bronchiolar and alveolar as well as peribronchial tissue inflammation (80) whereas two other studies have shown that inflammation is not more prominent in the peripheral than in the central airways (81, 82). Differences between these studies may relate to the sampling procedure because Kraft and coworkers used transbronchial biopsies (80) whereas the other investigators studied excised lung specimens (81). The site of the airways inflammation is of importance for the optimal target delivery of anti-inflammatory drugs.
The survival of inflammatory cells in airway tissues depends on survival factors. Apoptosis, a dynamic process involved in the control of the “tissue load” of cells at inflamed sites, tends to limit inflammatory tissue injury and promote resolution rather than progression of inflammation (83, 84). Because apoptosis attempts to terminate the inflammatory process by reducing the number of viable inflammatory cells within the bronchial mucosa, the persistence of inflammation may be due to alterations in the regulation of cell apoptosis leading to a chronic and self-perpetuating inflammatory cell survival and accumulation. Once at the site of airways inflammation, their survival as activated cells is increased (85) as a consequence of reduced apoptosis (86, 87) and possibly by increased expression of adhesion molecules on epithelial cells (77, 88). Increased eosinophil survival in asthma is associated with reduced apoptosis (86, 89). Several cytokines and chemokines may also promote cell survival, among them, GM-CSF, IL-3, IL-5, and RANTES, which are overexpressed in asthmatic airways (90-95). Antiasthmatic treatments may resolve inflammation by causing apoptosis (96). Glucocorticoids (97-99) and to a lesser extent theophylline (100, 101) reduce the survival of inflammatory cells including eosinophils.
Inflammation in chronic asthma appears to be far more complex than a simple eosinophilic inflammation alone (102). All cells of the airways, including T-cells, eosinophils, mast cells, macrophages, epithelial cells, fibroblasts, and even bronchial smooth muscle cells are involved in asthma and become activated. Nonetheless, eosinophils play an effector role by release of proinflammatory mediators (103-106), cytotoxic mediators (107), and cytokines (108-113), resulting in vascular leakage, hypersecretion of mucus, smooth muscle contraction, and epithelial shedding and bronchial hyperresponsiveness. These cells are also involved in the regulation of the airways inflammation and initiate the process of remodeling by the release of cytokines (108-112) and growth factors.
Epithelium: Epithelial cell shedding. For many years bronchial epithelial cells were considered to act mainly as a barrier participating in mucociliary clearance and removal of noxious agents. More recently epithelial cells have been found to participate in inflammatory reactions by the release of eicosanoids, peptidases, matrix proteins, cytokines, and nitric oxide (NO) as well as performing an immune function by their capacity to express human leukocyte-associated antigen-DR (HLA-DR) and present antigen.
In asthma, epithelium is partly shed (Figure 6), ciliated cells appear swollen, vacuolized and there is often loss of cilia (114, 115). When epithelium is reconstituted there are greater numbers of goblet cells than normal. In fatal asthma, extensive epithelial shedding is commonly observed (7). Epithelial cells of asthmatics are also significantly less viable than those of normal subjects (116).
The mechanisms underlying epithelial shedding in asthma are still a matter of debate (117). Epithelial shedding can be caused by plasma exudation (118), toxic inflammatory mediators such as eosinophil granule proteins (119, 120), oxygen free radicals, tumor necrosis factor-alpha (TNF-α) (121), mast cell proteolytic enzymes (103), or metalloproteases from epithelial cells (122) or macrophages (123). Furthermore, the increased epithelial fragility and shedding may also be caused by a weakened attachment of superficial epithelial cells to basal cells or to their basement membrane; this probably reflecting a disturbance in cell–cell adhesion (124).
The functional consequences of epithelial shedding are still unclear. Epithelial damage may lead to heightened airways responsiveness (125, 126), a failure to metabolize agonists (127), the destruction of a diffusion barrier altering permeability of the airway mucosa (128), the depletion of epithelial-derived relaxant factors (129) and loss of enzymes (neutral endoproteases) responsible for degrading proinflammatory neuropeptides including substance P (130). The integrity of airway epithelium may influence the sensitivity of the airways to provocative stimuli by liberating a variety of bronchoactive mediators, e.g., lipoxygenase and cyclooxygenase products (116, 131) and NO (132).
Epithelial cell activation. Activated epithelial cells release a wide array of mediators including 15-hydroxyeicosatetraenoic acid (15-HETE) (116), cytokines (133), eotaxin (134), growth factors (135, 136), extracellular matrix (ECM) proteins (116, 137), and metalloproteases (138) which can induce bronchial obstruction, inflammation, and airways remodeling (139).
In asthma, epithelial cells are activated releasing greater amounts of 15-HETE, prostaglandin E2 (PGE2), fibronectin, cytokines, growth factors, and endothelin spontaneously or after stimulation (116, 140). There is an increased expression of membrane markers such as adhesion molecules (77, 141, 142), endothelin (143), NO synthase (132), cytokines (144, 145) or chemokines (146). Epithelial cells can be activated by IgE- dependent mechanisms (147), viruses, pollutants (148), or proinflammatory mediators such as histamine (149).
Epithelial cells in airway remodeling. In asthma, epithelial cells are likely to be important in repair processes. They release ECM proteins (116) including fibronectin (137, 150) which appears to be of importance in cell regeneration. Bronchial epithelial cell–derived cytokines may amplify ongoing inflammatory processes via the recruitment and activation of specific subsets of inflammatory cells, as well as by prolonging their survival in the airway microenvironment (151). Bronchial epithelial cells represent targets for paracrine acting cytokines and growth factors, which may then modulate bronchial epithelial cell functions. They may be important in the regulation of airway remodeling and fibrosis as they release fibrogenic growth factors such as insulin growth factor (IGF) (135, 152) and transforming growth factor-beta (TGF-β) (153), they regulate fibroblast proliferation (154), and they release metalloproteases (155).
Inflammatory cells. Increased numbers of inflammatory cells are found among the epithelial cells. These include intact and degranulated eosinophils, lymphocytes, activated macrophages and partly degranulated mast cells (114, 156-158). Recently, it has been demonstrated that goblet cell hyperplasia precedes the inflammatory infiltrate and persists even after the number of inflammatory cells decreases, indicating that some of the phenotypic changes in airway epithelium are not caused by inflammation (159).
Mixed inflammatory infiltrate in the subepithelial layers: Eosinophils. Tissue eosinophilia is a characteristic of asthma but it is not necessarily specific to asthma (160). Eosinophils found in the airways of symptomatic asthmatics are activated (161, 162). Most allergic and nonallergic asthmatics, including those with mild asthma, have a bronchial eosinophilia and there is a significant association between eosinophil activation and asthma severity (76) as well as bronchial hyperresponsiveness (163). Tissue eosinophilia was found to be significantly greater in fatal asthma (164) than in patients with chronic asthma (165). Eosinophils are recruited and found to be activated during segmental allergen challenge (33, 166, 167). Soluble vascular cell adhesion molecule-1 (sVCAM-1) levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late-phase response (39).
The biological properties of eosinophils include the release of toxic granule proteins, oxygen free radicals, eicosanoids (sulfido-peptide leukotrienes) (168), Th2-like cytokines (169, 170), and growth factors (107, 171). Once activated, products from eosinophils contract human bronchial smooth muscle (172), increase vascular permeability (173), and induce airway hyperresponsiveness (174). Eosinophils are deleterious in asthma by the release of highly toxic products (major basic protein [MBP]; eosinophil cationic protein [ECP]; eosinophil-derived neurotoxin [EDN]; oxygen free radicals) which induce the shedding of the surface epithelium in keeping with the hypothesis of eosinophil-induced damage of the bronchi (107).
Eosinophils can be important cells of airways remodeling. Eosinophils can release growth factors (175, 176), elastase (177), and metalloproteases (178) involved in the process of tissue remodeling and fibrosis. Eosinophil products stimulate fibroblasts (179). Eosinophilia has long been associated with endomyocardial fibrosis (180) but the involvement of eosinophils in the fibrotic process is not completely understood. Eosinophils appear to be involved in pulmonary fibrosis (181) or in tropical pulmonary eosinophilia (182). Moreover, in an extensive study, MBP deposition was found to be present in some, but not all, cases of pulmonary fibrosis at the site of the fibrotic lesions (183).
Lymphocytes. Increased numbers of T lymphocytes are found in the airways mucosa of patients with fatal asthma (164) or in asthmatics of variable asthma causation including occupational asthma (163, 165, 184, 185). The majority of lymphocytes bear CD4-receptors whereas CD8-positive cells are more rarely identified, even during exacerbations of asthma (186). After allergen challenge there is an increase, in bronchial biopsies of asthmatics, of activated T cells and Th2 cytokines (29, 42). There appears to be an association between the severity of asthma and the number of CD4-positive cells in BALF (187, 188). T cells are also present in the inflammatory infiltrate of the airways in chronic bronchitic patients (189, 190), in which they are predominantly of the CD8 subset (191). Few B cells are present in the bronchi of asthmatics.
T cells are likely to play a role in controlling the chronic inflammation of allergic and nonallergic asthma by the release of Th2-cytokines (169, 192, 193). However, in stable chronic asthmatics T cells in the airways are also of the Th0 or Th1 phenotype (194, 195). Differences between allergic and non- allergic asthma have been observed in the BALF. In the allergic form of the disease IL-4, interferon gamma (IFN-γ), and IL-5 are measurable whereas in the nonallergic form IL-2, IFN-γ, and IL-5 but not IL-4 are found (196). However, these results have been subsequently challenged after examination of bronchial biopsies (11).
Mast cells and basophils. Mast cells are found in the bronchi of normal subjects and asthmatics (158, 163, 197, 198). They are often degranulated in the airways of asthmatics in both their stable phase and after allergen challenge (114, 199). In fatal soybean dust–induced asthma an activation of mast cells appears to be prominent (200). There are increased levels of tryptase, histamine, and PGD2 in the BALF (161, 199, 201– 203). The importance of mast cell activation remains to be fully understood because association between the severity of asthma and concentrations of histamine or tryptase in the BALF has been inconsistently observed (203, 204). Airway basophil and mast cell density in patients with bronchial asthma was associated in one study to bronchial hyperresponsiveness (198).
Mast cells appear to be critical “trigger” cells during episodes of acute asthma (161) eliciting acute bronchoconstriction, edema, and mucus secretion by the release of histamine and other vasoactive mediators such as PGD2 and cysteinyl leukotrienes. However, the role of mast cells is not confined to acute asthma and they may release neutral proteases including tryptase (103) and chymase. Tryptase has proinflammatory mast cell function (205) and potentiates histamine-induced contraction in human sensitized bronchus (206), whereas chymase exhibits procollagen proteinase activity (207, 208).
Mast cell products may have anti-inflammatory properties. Besides their activity as anticoagulants, heparin and heparan sulfate possess many biological activities that include the ability to modulate tissue homeostasis, wound healing, cell differentiation, cell proliferation (209), and inflammation (210, 211). Prevention of bronchoconstriction in exercise-induced asthma was observed with inhaled heparin (212). Heparin was shown to inhibit the immediate response to allergens in the lungs of allergic subjects (213, 214) and to reduce bronchial hyperresponsiveness (215).
Basophils and mast cells store preformed Th2-like cytokines which can be released during activation (41, 216-218). Mast cells and basophils can be induced to express CD40L. These studies suggest that mast cells and basophils can induce the synthesis of IgE, independently of T cells. The widespread expression of CD40 in normal epithelial cells suggests that the CD40–CD40L interaction has important, additional influences beyond that of regulating immune responses (219). The CD40 pathway may be important in the regulation of chronic inflammatory diseases. It has been suggested that the restricted basal epithelial cell expression of CD40 is associated with the cycling nature of these cells. CD40 expression has been shown to inhibit the growth of epithelial cells.
Mast cells may be involved in airways remodeling because they appear to have an important role in pulmonary fibrosis (220-222). Mast cells are potential sources of products stimulating migration and proliferation of fibroblasts, (223, 224). Mast cell lines can release components of basement membranes such as laminin and collagen IV (225) and angiogenic growth factors (226). Human mast cells activate fibroblasts, and tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis (227) and is a mitogen for epithelial cells (228).
Macrophages. Mononuclear phagocytes have a fundamental role in specific immunity via their accessory cell function and are metabolic cells which play a major role in chronic inflammation. The spectrum of their biologic activity is vast, and while many of the products released are involved in inflammation, they also take part in healing and repair.
Mononuclear phagocytes are likely to be involved in the pathogenesis of asthma because macrophages are among the cells present in the airways inflammatory infiltrate (157, 163, 229, 230), particularly in asthma of the nonatopic form (230). However, the increase in the numbers of macrophages in the airways is far greater in chronic bronchitis than in asthma or control subjects, particularly in bronchioles and surrounding alveoli (189, 191).
Alveolar macrophages (AM) recovered by BAL have been extensively studied in asthma, and most studies have revealed their increased activation (4, 231-235) and shown a significant correlation between their activation and the severity of asthma (236, 237). Endobronchial challenge with allergen has induced the activation of AM (19, 20, 33, 238); they are also activated during the late-phase reaction after allergen challenge (239). Cytokines that usually downregulate AM, such as IL-4, are less effective in asthmatic patients than in control subjects (234, 235).
Macrophages may also be involved in the generation of the airways obstruction and the regulation of the airways inflammation through release of enzymes (231), eicosanoids (240), platelet-activating factor (PAF) (241), oxygen free radicals and cytokines (233, 234), and mucus secretagogues (242) that are likely to be deleterious for the bronchi. Macrophages can also modulate the immune response (243, 244).
Macrophages may also be involved in the regulation of the airway remodeling through the secretion of growth-promoting factors for fibroblasts, cytokines, and growth factors such as platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), or TGF-β possibly involved in fibrosis (245). In interstitial lung diseases, AM were found to be activated and to release cytokines, plasminogen activator, and a fibrinolytic inhibitor (246-248) as well as MIP-1α, a peptide with leukocyte-activating and chemotactic properties (249). In lung inflammation, an increased expression of PDGF β chain is expressed in AM of patients suffering from interstitial pulmonary fibrosis (250-253). By comparison to normal subjects, AM from asthmatics release increased amounts of TGF-β and fibronectin, but to a lesser extent than those of chronic bronchitis patients (254). They also express PDGF-β mRNA in vivo in asthma (255). Macrophages can also synthesize and secrete a group of matrix metalloproteinases (MMP) having the capacity to degrade various ECM macromolecules including elastin. MMP-9 release by AM is increased in asthmatics by comparison to control subjects and chronic bronchitics (123). It is likely that macrophages participate in most processes in healing from acute and chronic inflammation through angiogenesis (256), proliferation of endothelial and mesenchymal cells, and the regulation of ECM synthesis and degradation possibly leading to fibrosis (257).
Polymorphonuclear neutrophils. The role of neutrophils in stable asthma remains unclear. Although recovered in the sputum of asthmatics (258), neutrophils are usually found in low numbers in BAL (160) and bronchial biopsies (125, 160, 163) from asthmatic subjects. However, neutrophils are increased in the airways during the late-phase reaction after an allergen challenge (31, 32), in some patients who died within hours after an asthma exacerbation (259, 260), in nocturnal asthma (261), in some patients with long-standing asthma (262), or in patients with corticosteroid-dependent asthma (263).
Dendritic cells. There is a network of dendritic cells within the epithelium of the conducting airways of humans that constitutively express major histocompatibility complex (MHC). Dendritic cells may be critically important to the induction of immune responses within the airways as they are specialized in antigen processing and presentation. In animals, the dendritic cell population in the airway epithelium is renewed every 48 to 72 h (264). It appears that dendritic cell number can be altered after exposure to topical and systemic corticosteroids (265). Dendritic cells in normals and asthmatics express the Fcɛ RI (266); their numbers are greater in the airways of asthmatics compared with those of control subjects (267, 268); but their role in asthma is still a matter of debate (269).
Fibroblasts and myofibroblasts. Fibroblasts are frequently found in connective tissue. They are responsible for the production of collagen, reticular and elastic fibers as well as for the synthesis of proteoglycans and glycoproteins of the amorphous intercellular substance (270). Human lung fibroblasts may behave as inflammatory cells upon activation by IL-4 and IL-13 (271). Although they are regarded as fixed cells of connective tissue origin, they retain the capacity for growth and proliferation and are a pluripotent cell. They may be precursors for various cell types including smooth muscle cells (272). Cell cultures from media obtained from bronchial subepithelial myofibroblasts enhances eosinophil survival in vitro (273). The myofibroblast may potentially contribute to the regulation of bronchial inflammation via the release of cytokines (274) and to tissue remodeling by its release of ECM components such as elastin, fibronectin, and laminin (275). In pulmonary fibrosis there is an increased production of ECM components by myofibroblasts (276). During the late-phase reaction after allergen challenge, myofibroblasts increase from the normal of 2% of cells to approximately 15% within a day, and ultrastructural forms of cells between fibroblast and bronchial smooth muscle have been found (272). Restoration of normal tissue structure after injury often coincides with the loss of the myofibroblast phenotype and the reappearance of normal-appearing fibroblasts (275).
In asthma, myofibroblasts are increased in numbers beneath the reticular basement membrane (Figure 7), and there is an association between their numbers and the thickness of reticular basement membrane (277, 278).
Platelets. The importance of platelets in asthma remains unconfirmed (279, 280). They have been described at sites of epithelial sloughing together with fibrin in cases of mild symptomatic asthma (125). They are activated in aspirin-induced asthma (281) and nocturnal asthma (282).
Neurogenic inflammation. Neural mechanisms and their interaction with inflammatory cells are likely to be important in the pathophysiology of asthma. Inflammatory mediators may influence the release of neurotransmitters or may activate afferent nerves leading to bronchoconstrictive reflexes and the release of mucins at sites distant to the initiating event. This spread of inflammatory effects along the airways is referred to as a neurogenic inflammation (283-286). Neurogenic inflammation is probably not relevant to mild asthma, however, but it may be more important in severe disease such as brittle asthma (287). Inflammation upregulates neurotrophins in asthma, possibly contributing to airway hyperresponsiveness (288).
Eicosanoids. No single mediator is responsible for the clinical and pathologic events in bronchial asthma, but there is now substantial evidence that the cysteinyl leukotrienes (LTC4, LTD4, LTE4) play an important role in the pathophysiology of asthma (104, 289-291). Cysteinyl leukotrienes are released by most cells involved in the airways inflammation and particularly by eosinophils (292). Cysteinyl leukotrienes are potent in eliciting bronchoconstriction (293, 294), increase endothelial membrane permeability leading to airway edema, enhance secretion of mucus (295), and may increase bronchial hyperresponsiveness (296, 297). Cysteinyl leukotrienes may also be of importance in inflammation because inhalation of LTE4 (298) or LTD4 (299) induces the recruitment of eosinophils in the airways, possibly in part by inducing P-selectin expression on endothelial cells (300), and they have been shown to have an important role in airway eosinophilia in an animal model of asthma (301).
However, cysteinyl leukotrienes may also alter remodeling because they increase proliferation of airway smooth muscle (302, 303) and airway epithelial cells (304) and LTC4 was shown to upregulate collagenase expression in human lung fibroblasts (305).
Several lines of evidence support the central role of the cysteinyl leukotrienes in aspirin-sensitive asthma (306, 307). There is a profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients (308).
The response of patients to drugs may vary depending on genetic factors. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that may modify transcription factor binding and reporter gene transcription have been reported (309), and this may explain the response of patients to 5-lipoxygenase inhibitors.
Other proinflammatory and anti-inflammatory mediators: Endothelins (ETs). Endothelins are a family of 21 amino-acid regulatory peptides which appear to have a role in the regulation of pulmonary functions. ET immunoreactivity was found to be expressed at a higher level in bronchial biopsies of asthmatic patients (143), and levels of ET are elevated in BALF (310) and bronchial biopsies (311) of asthmatics compared with normal subjects. Moreover, endothelin levels are increased in BALF in nocturnal asthma (312). Endothelins are released from macrophages (235), endothelial and epithelial cells (313). The potent bronchoconstrictor and mitogenic actions of ET-1 on airway smooth muscle may contribute significantly to the increased muscle mass and bronchial obstruction observed in asthma (314). ET also possess proinflammatory properties (315) and oxygen free radicals (316).
Nitric oxide (NO). NO is an intercellular transmitter, both in the central and in the peripheral nervous system. In addition to nerve cells, NO is also produced by epithelial cells and by the endothelium. NO plays a key role as a vasodilator, neurotransmitter, and inflammatory mediator in the airways and is produced in increased concentrations in asthma (317). It may be the major bronchodilator of airways normally (318). However, NO may have deleterious effects on the airways as a vasodilator, by increasing plasma exudation, and may also amplify the asthmatic inflammatory response. Proinflammatory cytokines and oxidants increase the expression of an inducible form of NO synthase (iNOS) in airway epithelial cells in asthma (132), and this may be the explanation for the increased concentrations of NO found in exhaled air of asthmatic patients (319).
Inflammation can be demonstrated in allergic (163), nonallergic (11, 94, 230), occupational (185, 320, 321) and aspirin- induced asthma (307, 322). The profile of inflammatory cells and cytokine gene expression appears to be similar in allergic and nonallergic asthma, although the presence or absence of IL-4 protein in nonallergic asthma has been debated (11, 94, 184, 230, 323-325). Chronic inflammation may be induced or acutely increased by exposure to allergens (326), occupational agents (327, 328), pollutants (329-331), or a virus infection (332-334).
Inflammation occurs early in the course of asthma process (335), in patients with mild intermittent asthma (336) and during remissions (262). The severity of asthma has been correlated with many inflammatory indices such as epithelial denudation (125) and activation (77, 116, 337), eosinophil number and activation (76, 187, 338), T-cell activation (230), macrophage activation (236, 339), or cytokine expression (144). However, inflammation does not explain all the components of asthmatic phenotype (78).
In nocturnal asthma, several studies have shown increased airway eosinophils and neutrophils (261, 340, 341), superoxide (342), and cytokine concentrations (112) as well as activation of lymphocytes and macrophages (343) when bronchoscopy with BAL or mucosal biopsies were performed during the night. Histamine (344, 345) and ECP concentrations (346) were increased in the peripheral blood during the night. These findings are of importance because asthma is an inflammatory process which worsens at night in some patients (343, 347). However, other mechanisms may also be responsible for nocturnal asthma. The Gly16 polymorphism of the β2 adrenergic receptor, which imparts an enhanced downregulation of receptor number, is overrepresented in nocturnal asthma and appears to be an important genetic factor in the expression of this asthmatic phenotype (348).
Chronic inflammation is associated with nonspecific bronchial hyperresponsiveness and induces exacerbations. Exacerbations are characterized by symptoms or worsening of asthma over a period of days or even weeks (349-351). Although exacerbations need to be better characterized, they are usually separated into mild and severe. In a recent study (352), mild exacerbations were defined as a reduction in morning peak flow rates under 20% baseline values or an increased need for rescue β2-agonists or of nocturnal asthma. However, single isolated days were not considered as exacerbations. In the same study, severe exacerbations were defined as ones requiring treatment with oral glucocorticoids, as judged by the investigator, or a decrease in the peak flow rates as measured in the morning to > 30% below the baseline value on two consecutive days.
Nonspecific bronchial hyperresponsiveness may be defined as an increase in the ease in degree of airway narrowing in response to a wide range of bronchoconstrictor stimuli (353, 354). Several mechanisms have been identified in bronchial hyperresponsiveness which has a heritable component and is closely related to serum IgE levels and airway inflammation (355). Reduced airway caliber, increased bronchial contractility, dysfunctional neural regulation, altered permeability of the bronchial mucosa, proinflammatory humoral and cellular mediators (356), and cytokines such as GM-CSF (144) and TNF-α (357) are critical factors for bronchial hyperresponsiveness. Nonspecific bronchial hyperresponsiveness has been associated with epithelial injury (125, 126, 358), increased airway microvascular permeability (359, 360), inflammatory cells in the airways (28, 46, 126, 144, 244, 361), and features of remodeling (362). However, not all studies have found an association between inflammation and nonspecific bronchial hyperresponsiveness (363). Moreover, the degree of airway inflammation was shown to correlate with the magnitude of bronchial hyperresponsiveness (125, 188, 361).
The treatment of exacerbations is based on long-term control medications including corticosteroids, cromoglycate, and nedocromil, long-acting β2 agonists, methylxanthines, and leukotriene modifiers (2, 13, 14).
Although the inflammatory nature of asthma is not completely understood (364), corticosteroids remain the most potent anti-inflammatory drugs for use in the treatment of asthma (365-367). Glucocorticoids have an inhibitory effect on inflammatory and immune responses primarily through the modulation of transcription factors binding to DNA such as activator protein-1 (AP-1), nuclear factor kappa B (NF-κB) (368), and cyclic adenosine monophosphate (cAMP)-responsive element binding protein (CREB). The effects of glucocorticoids in asthma are widespread but they can reduce cytokines that are involved in cell recruitment and the survival of inflammatory cells including eosinophils, basophils, and lymphocytes (369). In most but not all studies, inhaled corticosteroids (90, 145, 146, 370-380) and oral corticosteroids (186, 381-388) have been shown to reverse many of these inflammatory indices. Moreover, a temporal association between the reduction of inflammatory indices and clinical and physiologic improvement has been observed (384). In patients with mild to moderately severe asthma, inhaled corticosteroids significantly reduce exacerbations, improve pulmonary function, and reduce nonspecific hyperreactivity. Inhaled corticosteroids are, however, poorly effective in preventing virus-induced exacerbations (389). There is, however, a very small but still clinically important subset of asthmatics who may not respond favorably to oral corticosteroids (390, 391).
Asthma exacerbations can be treated or reversed to a lesser extent by cromones (392) and theophylline. Nedocromil sodium in studies of bronchial biopsy was not found to alter airways inflammation (393, 394) but did reduce the eosinophil influx into airways after segmental antigen challenge (395). Disodium cromoglycate was also found to reduce inflammation and adhesion molecules in the airways in a biopsy study (396). Theophylline (397–400) has been found to reduce airways inflammation.
Cysteinyl leukotriene antagonists (401, 402) and 5-lipoxygenase inhibitors (403, 404) are effective in the treatment of asthma but their exact roles are currently under investigation. Zileuton, a 5-lipoxygenase inhibitor (405) and cysteinyl leukotriene antagonists (406) have been found to reduce airways inflammation.
Salmeterol was not found to reduce airways inflammation (407, 408) although it reduces basophil hyperreleasability in peripheral blood (409) and eosinophil activation in vitro (410). However, although it is very difficult to compare the relative anti-inflammatory activities of drugs because they are not compared in the same study, nonsteroidal drugs appear to be less potent than corticosteroids.
Because asthma often presents with association of symptoms and exacerbations, treatment that combines inhaled corticosteroids and long-acting β2-agonists has been shown to control optimally chronic asthma (352, 411–413). However, other treatment options may be taken such as combination of theophylline (414) or leukotriene antagonists (402) with inhaled steroids.
Inflammation is an early feature of asthma (335, 415) and it has been proposed that anti-inflammatory treatment should begin as soon as asthma is diagnosed (416). Even patients with mild intermittent asthma present an airways inflammation suggesting that anti-inflammatory drugs should be administered in mild asthma (2, 417). Moreover, it has been observed clinically that patients relapse within days or weeks after cessation of inhaled corticosteroid treatment (418, 419). It is therefore considered essential to continue anti-inflammatory treatment over a prolonged period.
Acute inflammation is a beneficial, nonspecific response of tissues to injury and generally leads to repair and restoration of the normal structure and function. In contrast, asthma represents a chronic inflammatory process of the airways followed by healing whose end result may be an altered structure referred to as a remodeling of the airways (420). Repair usually involves two distinct processes: regeneration, which is the replacement of injured tissue by parenchymal cells of the same type; and replacement by connective tissue and its eventual maturation into scar tissue. In many instances both processes contribute to the healing response and inflammation. In asthma the processes of cell dedifferentiation, migration, differentiation, and maturation as well as connective tissue deposition can be followed either by complete or altered restitution of airways structure and function, the latter often seen as fibrosis and increase in smooth muscle and mucus gland mass (421) (Figure 8).
Structural changes in the airways of asthmatics. In addition to other inflammatory features, the airway wall of patients with asthma is usually characterized by an increased thickness involving an increase in muscle mass and mucous glands, and in vessel area leading to a thickened airway wall and a markedly and permanently reduced airways caliber (Figures 9 and 10). These features were observed as well using computed tomographic (CT) scans (422, 423) and result in an increased resistance to airflow, particularly when there is bronchial contraction and bronchial hyperresponsiveness (422, 424). The effect on airflow is compounded by the presence of increased mucous secretion and inflammatory exudate, which not only blocks the airway passages but causes an increased surface tension favoring airway closure.
Hypertrophy and hyperplasia of airway smooth muscle. Smooth muscle mass is usually increased in large and/or small airways in both fatal and nonfatal cases of asthma (425–429). The increase in muscle mass is often not seen in chronic bronchitis and chronic obstructive pulmonary disease (COPD), and, if present is increased in the small airways (426, 427). There is a 3- to 4-fold increase in muscle volume in asthmatic airways by comparison to normal subjects (430). In some patients the muscle may occupy up to 20% of the bronchial wall (425). However, while an increase in smooth muscle in the major bronchi has been reported in asthmatic subjects (425), an increased smooth muscle thickness was also found in the peripheral airways (428, 429). Interestingly, in a study of asthmatic patients who died from other causes no hyperplasia or hypertrophy were observed (431). More recent studies have indicated some degree of heterogeneity of the smooth muscle thickening (432, 433). In most patients the increase in muscle mass was most pronounced in large bronchi but some patients had increased muscle mass which involved the entire airway tree including bronchioles.
Smooth muscle cells are multifunctional mesenchymal cells capable of expressing considerable phenotypic plasticity (434). Increases in smooth muscle mass may be due to several factors, including the following: proliferation of smooth muscle induced by inflammatory mediators (435), cytokines (436), and growth factors (437, 438); a “work hypertrophy” resulting from repeated episodes of bronchospasm; or reduced inhibitory control resulting in myogenic activity and hypertrophy. The accumulation of enriched plasma in the environment surrounding airway smooth muscle may also promote smooth muscle mitogenesis and hyperplasia (439). It has been suggested that an intrinsic abnormality of smooth muscle may underlie asthma severity, but data are lacking to support this hypothesis.
In addition to contractile responses and mitogenesis, airway smooth muscle cells have synthetic and secretory potentials with the release of RANTES (440). They may participate in chronic airway inflammation by interacting with both Th1- and Th2-derived cytokines to modulate chemoattractant activity for eosinophils, activated T lymphocytes, and monocytes/ macrophages. Smooth muscle also has the potential to alter the composition of the ECM environment and orchestrate key events in the process of chronic airway remodeling (441).
There are many functional consequences of the increase in bronchial smooth muscle mass. It has been proposed that the same degree of muscle shortening may cause considerably greater lumenal narrowing in an airway with a thick wall than in a normal airway (442, 443). This has been confirmed by computer modeling of the tracheobronchial tree that examines the interaction between airway smooth muscle shortening, airway wall thickening, and changes in pulmonary resistance (444– 446). Unlike the human lung, the model is based on the symmetrical dichotomous branching tracheobronchial tree. The model has shown (446) that the marked increase in airway wall thickness equivalent to that seen in asthma does not reduce the airways caliber if the airway smooth muscle remains at its resting length. As bronchoconstriction occurs, there is a marked increase in airway resistance (444, 447), and studies of human lungs have shown that the smooth muscle in asthmatic airways needs to shorten by only 40% of its resting length to completely occlude the airway lumen (445). The model also shows that resistance, particularly in the small airways, tends to reach a plateau in normal airways, whereas it increases progressively in asthma because of airways closure (445, 446). These calculations are consistent with observations made during bronchial challenges where, in normal subjects, the reduction in FEV1 reaches a plateau, whereas in asthmatics, the FEV1 continues to decrease without a plateau occurring (448).
Increase in mucous glands. Mucous glands are distributed throughout the cartilaginous airways in the normal and in asthma where they may be even present in peripheral bronchioles where normally they are absent. Hypertrophy of the submucosal gland mass is thought to contribute to the excessive mucus production in fatal asthma. The glands make up a higher proportion of the submucosa in fatal asthma compared with normal subjects (425, 429, 449). Another feature of the glands is dilatation of the secretory ducts that lead into the bronchial lumen, a condition referred to as bronchial gland duct ectasia (450, 451). This may be associated with the interstitial emphysema observed in some asthmatic patients using CT scan (452). The increase in the number of epithelial goblet cells also contributes to the excess of mucus secretion into the lumen (453, 454) and the secretions present in large airways may be aspirated to smaller airways.
Mucous plugs occur in airways of all sizes, from the second generation airways to bronchioles (455). Although some patients may die from cardiac arrhythmia or overwhelming smooth muscle spasm without mucus hypersecretion (456), most patients have an excessive mucus production (457–459) leading to endobronchial mucous suffocation. Over 50% of the airways may be occluded by mucus during a fatal attack of asthma (428). The greater mucous viscosity may significantly reduce mucociliary clearance (460). Large and small airways become plugged with secretions and inflammatory exudate which are so viscid that patients are poorly responsive to high-dose inhaled bronchodilators (456), and the mucus may need to be removed by bronchoscopy and lavage.
Thickening of the reticular basement membrane (i.e., lamina reticularis). The basement membrane of surface epithelium is composed of several layers: the basal lamina (referred to as the “true” basement membrane) and the lamina reticularis. The thickening of the lamina reticularis is a characteristic early typical feature of the asthmatic bronchus (425) which is caused by deposition of reticulin (461). By light microscopy, this is homogeneous and hyaline in appearance. Ultrastructurally, it appears to consist of a plexiform arrangement of the fibrils in an amorphous matrix. The basal lamina is of normal thickness in asthma, whereas the reticular layer is thickened associated with deposition of immunoglobulins and/or collagen I and III and fibronectin but not collagen types V and VII (462) nor laminin (463). The additional reticulin is likely produced after activation of myofibroblasts (277) leading to a so-called “fibrosis” of the airways. The thickening has not been related to the severity, duration, or origins of asthma in some studies (125, 464) whereas a correlation with the severity of the disease has been observed in another one (465). Patients with rhinitis also present with subepithelial fibrosis of the bronchi with a deposition of type I and III collagen and fibronectin. However, these features are less marked than in asthma (466). In contrast, there is a lack of such thickening in COPD (160, 191, 467). The connective tissue of the airways forms a “scaffold” for the replicating parenchymal cells, and its abnormal structure in asthmatic airways may result in several defects and induce a remodeling of the airways which is detrimental to airflow (422).
Blood vessels. There is a rich network of systemic capillaries running immediately beneath the surface lining from central airways to peripheral bronchioles. The subepithelial tracheobronchial capillaries converge and extend to a deeper plexus of larger sinuses which anastomose with the pulmonary capillaries drained by pulmonary veins. Transmission electron microscopy (TEM) demonstrates that the bronchial vessels are adjacent to the epithelial basement membrane, and do not lie in the epithelium itself. These vessels are critical to chronic inflammatory process when they dilate and possibly proliferate. New vessels originate by budding or sprouting of preexisting vessels, a process called angiogenesis (468). Wherever angiogenesis has been studied, the newly generated vessels have been found to be hyperpermeable and increase edema.
In asthma, there is an increase in vessel area (428, 469) leading to a thickened airway wall (445). Bronchial biopsies from patients with mild asthma are more vascular than those of normal control subjects, there are more vessels in asthmatic airways, and asthmatic bronchial vessels are larger than that of control subjects (470). Moreover, in asthma there are endothelial gaps in the bronchial mucosal microvasculature whereas they are not detected in tissue from normal healthy individuals (471).
Various endothelial growth factors have been described (472) and include vascular endothelial growth factor (VEGF) (473), bFGF, platelet-derived endothelial cell growth factor (PD-ECGF) and hepatocyte growth factor (HGF). A number of putative angiogenic factors including small molecules (e.g., prostaglandins, adenosine) as well as many cytokines and growth factors (e.g., TGF-α, bFGF, TGF-β, TNF-α, PDGF) have all been shown to upregulate VEGF expression. The inhibitory effect of corticosteroids on VEGF expression could explain the clinically well-known antiedematous potency of corticosteroids on a molecular level (474).
ECM components. Connective tissue cells produce and secrete an array of macromolecules forming a complex network filling the extracellular space of the airway wall called the ECM. The macromolecules that constitute the ECM are secreted locally by all cells present. The composition of the matrix secreted depends on the cell types, their state of differentiation, and their metabolic status. Molecules comprising ECM consist of fibrous proteins (collagen, elastin), structural or adhesive proteins (fibronectin and laminin) embedded in a hydrated polysaccharide gel containing several glycosaminoglycans including hyaluronic acid or hyaluronan (HA). The glucosaminoglycans, proteoglycans, and structural proteins entrap water molecules to form a highly hydrated gel-like “ground substance” in which the insoluble fibrous proteins are embedded, giving the matrix strength, rigidity, and resilience. Until recently, the ECM was thought to be an inert scaffolding having a mechanical role in supporting and maintaining tissue structure. However, it has been shown that the ECM also modulates a multitude of cell functions such as development, migration, and proliferation (475, 476). ECM abnormalities in asthma are still poorly understood but may be of major importance (477).
Collagen is a major protein of the ECM (478). In some asthmatics hyperplasia of collagen fibers can be observed. These fibers may be irregularly disposed but the exact nature of collagen is not completely characterized. The subepithelial tissues of asthmatics contain significantly more collagen type I and III than that of normal control subjects (479) and such “scar formation” may have greater functional implications than the increase in thickness of the reticular basement membrane.
Tenascin and fibronectin are ECM glycoproteins expressed during morphogenesis and tissue repair. An increase in tenascin immunoreactivity was observed in the bronchial subepithelial reticular basement membrane layer in patients with chronic asthma and in those with seasonal asthma compared with control subjects (480). The tenascin immunoreactivity, appearing as an intense wide subepithelial band in asthma, was seen only occasionally in the basement membrane of control specimens. Instead, a diffuse immunoreaction against both total fibronectin and locally produced extradomain A fibronectin was similarly visible in the airway mucosa of both patients and control subjects. There was no correlation between the number of eosinophils or lymphocytes and level of tenascin expression, suggesting that the higher amount of tenascin reflects disease activity in asthma and may be an indicator of a remodeling process rather than of injury itself.
Elastin is a cross-linked protein that gives tissues their elastic recoil and is a requirement for tissues that bend, twist, and stretch reversibly. Subepithelial elastic fibers of the airways are fragmented. In the deeper layer, fibers are often patchy, tangled, and thickened (481) but the total amount of elastic fiber appears to be unchanged (482).
Glycosaminoglycans form an important component of ECM binding to water and cations (483). HA is normally found in adult tissues in small amounts but is present in higher amounts during wound healing (484). It confers important physical properties, notably viscoelasticity, and facilitates cell migration and proliferation during injury and repair (485). HA levels are increased in the BALF of asthmatics, and their level is associated with the severity of the disease (204).
The ECM is a dynamic structure, and an equilibrium between synthesis (486) and controlled degradation of ECM components is required for the maintenance of its homeostasis. Three major elements are involved: proteases and protease inhibitors (487, 488), cell receptors recruiting intracellular and secreted proteases to the cell surface, and integral membrane proteases activating a protease cascade. Eosinophils (178) and macrophages act as a source of MMP-9 in asthmatic airway inflammation (123). Elastase was found to be released in increased amounts in the sputum of asthmatic patients by comparison to control subjects, and, elastase concentrations were significantly correlated with FEV1 (489).
Structural changes in the parenchyma of asthmatics. In the pathologic examination of asthmatic lungs, mild emphysema, a destructive process focusing on the acinus, was described in some rare cases (431, 490) but is not a usual feature (425, 449).
Fibrogenic growth factors. Growth factors interact with the ECM (491) and can be divided into fibrogenic and hematopoietic (245). TGF-β is considered to be a major fibrogenic cytokine (245, 492). The TGF-β family comprises several isoforms of TGF-β which can be generated by several cells including macrophages, epithelial cells, fibroblasts, and eosinophils (175, 492). In a normal lung, bronchial epithelium expresses TGF-β (493). PDGF can be produced by most inflammatory cell types of the airways inflammation and appears to be involved in tissue repair via the induction of migration and proliferation of connective tissue cells and proliferation of smooth muscle (494, 495). On the other hand, epidermal growth factor (EGF), which promotes healing by stimulating the proliferation and migration of epithelial cells and increasing the synthesis of proteins such as fibronectin (496), is not considered a fibrogenic cytokine per se (245) although it was found to have some fibrogenic properties (497). GM-CSF, an important hematopoietic growth factor involved in eosinophil and macrophage accumulation in tissues, is considered a nonfibrotic growth factor (245).
TGF-β expression was found to be increased in asthma in some (498) but not all studies (499, 500), and its compartimentalization is altered (501). TGF-β is even more highly expressed in chronic bronchitis (498). TGF-β was also found in increased concentrations in the BALF of asthmatics by comparison with control subjects and these levels increase further in response to allergen exposure (502). In asthma, bronchial eosinophils express increased levels of TGF-β (498, 503). The increased expression of TGF-β was significantly correlated with two markers of remodeling, the thickness of the reticular basement membrane and the number of fibroblasts both in asthma and chronic bronchitis (498). The expression of EGF is also increased in asthma and chronic bronchitis, but there is no correlation with fibrosis patterns. PDGF expression is not increased in the airways of asthmatics (500, 504, 505) although PDGF (506) mRNA transcripts are found in eosinophils in asthmatics patients. IGF-1 expression is not increased in the airways of asthmatics (500). These results in asthma may explain, in part, why the remodeling of the airways in asthma is a slow process whereas fibrotic diseases of the lung in which PDGF or IGF appear to be involved, may rapidly evolve toward severe fibrosis (507).
Irreversible component of the airways obstruction. For decades, asthma has been considered as a condition of reversible airflow obstruction, and, in the majority of patients, complete reversiblity of long-standing abnormal spirometric measurements, such as FEV1 may be observed after bronchodilators and/or a course of corticosteroids. However, many asthmatic patients, both children and adults, have evidence of residual airway obstruction (508–512) which may be detected in asymptomatic patients (513) and may be observed months after cessation of asthmatic symptoms in perfectly asymptomatic patients (508, 513, 514). Studies in which lung function changes have been examined have shown that the FEV1 is decreased mainly in subjects with persistent asthma but objective measures of the small airways are usually not performed (513, 515, 516). It has been shown that peripheral lung resistance is increased in asymptomatic asthmatics with normal FEV1 (517). However, this irreversible component of the airways obstruction is more prominent in severe patients (512) and persists in some patients even after a long-term treatment with inhaled corticosteroids (518). Asthmatic children or adults are heterogeneous with regard to the degree of reversiblity of airflow limitation. Although studies are difficult to compare, it appears that irreversible airways obstruction is usually associated with the frequency of wheezing and the ongoing presence of asthma (519, 520). Moreover, patients with severe asthma are those who more commonly develop an irreversible airflow obstruction (521).
During adult life, asthma is often associated with an increase in the rate of decline in FEV1 (519, 522–526). However, symptoms may remain unchanged while lung function deteriorates (527). In middle-aged and elderly smokers it is difficult, in some patients, to separate chronic bronchitis and asthma by means of FEV1 (528, 529) and responses to bronchodilators (530). Bronchial hyperresponsiveness appears to be inconstantly associated with an increase in the rate of decline of lung function (515, 524). Atopy (531) and smoking are also associated with an increased decline of lung function (519, 531). However, the effect of asthma is variable and not all subjects with asthma have steep rates of decline. It appears that asthma starting after the age of 50 yr elicits a steeper rate of decline than asthma with an earlier onset (532). It has also been shown in some (526, 533) but not all studies (525) that nonallergic asthmatics have a steeper rate of decline of FEV1. However, there is no prospective study showing that structural changes, pulmonary function parameters, and indices of inflammation are related longitudinally.
The prognostic implications of the incomplete reversiblity, observed in some asthmatics, remain to be determined but chronic sequelae of asthma may lead to complications including severe symptomatology and work disability (534). Whether residual irreversible air flow limitation in individuals with asthma or a history of asthma could have been prevented either by early and aggressive pharmacologic treatment or by limitation of exposure to smoke or other noxious environmental agents is another question which needs more data to be fully answered (518, 535–538).
Loss of elastic recoil. In asthma, most studies of moderately severe asthmatic patients in the stable state have found some loss of the elastic recoil and lung elasticity (539–543). These abnormalities may be related to the combined effects of reduced elastic recoil per se and airways obstruction, but the inhalation of isoproterenol has been shown to decrease airways obstruction and is associated with a further decrease of elastic recoil (541). These findings favor an intrinsic abnormality.
Conclusions. Taken together, these studies indicate that many asthmatics have physiologic abnormalities even when they are asymptomatic and under symptomatic control with anti-inflammatory treatment (Figure 11). This may be due to persistent underlying bronchial inflammation and/or the degree of airway remodeling shown to be present in most patients even when they are asymptomatic.
In asthma, high-resolution computed tomography (HRCT) is abnormal in about two-thirds of the patients (452). Reversible abnormalities include mucoid impactions, alveolar syndrome, and lobar collapse. Irreversible abnormalities include bronchiectasis without clinical implication, bronchial wall thickening, secondary line shadows, and emphysema-like images only minimally present and in most cases due to a cicatricial peribronchial fibrosis (452, 544, 545). Most of these abnormalities are likely related to bronchial destruction. In a study examining the patterns of HRCT scans in 126 asthmatics of variable severity and causes, it was found that there was an increase in fixed abnormalities that were dependent upon the severity of asthma. Patients with nonallergic asthma were also found to have a significantly greater number of fixed abnormalities than those with allergic asthma (546).
A relationship between asthma and emphysema was suggested in 1952 by Royle who found emphysema in patients with severe asthma (547). However, the study was compromised because chest X-rays fail to recognize mild emphysema and most of the patients studied were current smokers or ex-smokers. Some studies have found that emphysema may be present in a small subset of asthmatics (545, 546, 548, 549). However, it seems that instead of direct destruction of the distal airspace, the respiratory airspace enlargement may be produced by fibrotic change and airway remodeling (550, 551).
The effects of anti-inflammatory drugs on the process of airways remodeling have not been studied adequately (552). Inhaled steroids did not reverse the thickening of this reticular layer in atopic asthma (553) even after a long-term treatment (554, 555). However, in two other studies in mild asthma inhaled steroids were found to reduce this thickening (378, 556). Inhaled steroids were found to reduce the tenascin in the basement reticular membrane (480). In animals, cyclosporin A was shown to inhibit airway reactivity and remodeling after chronic antigen challenge (557). This will form an important future research area in human studies.
The efficacy of anti-inflammatory treatment on the natural course of asthma is still debated as the longest prospective studies available do not exceed 5 yr. In childhood, lung growth and the effect of alveolar wall attachments to small airways suggest that the early use of anti-inflammatory treatment is favored. It seems that inhaled corticosteroids can reduce the accelerated decline of the pulmonary function or bronchial hyperresponsiveness both in children and adults (536, 537, 558– 561) but the effects appear to be incomplete (518). However, there is no evidence that undertreatment of asthma would induce deterioration in the long term. Moreover, it is not known whether very long courses of treatment with inhaled steroids (for 20 to 30 yr) may induce bronchial and systemic side effects, especially when the treatment is started very early in life. These considerations emphasize the need to develop more specific and incisive treatment for the asthmatic condition.
Studies of airways in chronic asthmatics by bronchoscopic methods and induced sputum have provided much helpful and insightful data. Within the past 20 yr such studies have led to a better understanding of the mechanisms of inflammation and pathogenesis of asthma. Experiments such as the bronchial challenge with allergen provide valuable insights into the allergic inflammatory response but we still do not understand how this may influence or lead to a remodeling process. The recent availability of genetically altered animals lacking genes for selected cytokines and growth factors, so-called transgenic mice, and those whose genes have been enhanced, so-called transgenic overexpressor mice, may prove useful in the elucidation of the role of individual factors in the overall inflammatory cascade and the remodeling process.
Asthma involves acute mechanisms including bronchospasm and edema and the production of mucus which can be altered by the use of bronchodilators. However, in chronic airways inflammation, guidelines have highlighted the importance of anti-inflammatory treatment (Figure 12). Is remodeling of the airways a proven clinical concept? It is clear that changes in the ECM have the capacity to influence airway function in asthma. However, it is not known how each of the many changes that occur in the airway wall contributes to altered airway function in asthma. In asthma, remodeling is almost always present in biopsies, as shown by collagen deposition on the reticular basement membrane, but is not always clinically demonstrated. Destruction and subsequent remodeling of the normal bronchial architecture are manifested by an accelerated decline in FEV1. This irreversible component of the airway obstruction is more prominent in severe patients and even persists after an aggressive anti-inflammatory treatment. There are other clinical consequences of remodeling. The increase in smooth muscle mass can lead to a severe bronchial obstruction during an asthma attack. Mucous glands are sometimes enlarged and may induce an excessive mucus production. The ongoing inflammation and subepithelial fibrosis are linked with the persistence of exacerbations and nonspecific bronchial hyperresponsiveness. Degradation and/or reorganization of elastin and cartilage may result in decreased airway wall stiffness and increased airway narrowing for a given amount of force generated by the smooth muscle. Thus, the process of airway wall remodeling is still not understood and requires investigation into its mechanisms and the role of drugs in its reversal and prevention (Table 1).
|1.||Need for a standardized consensus definition of airways remodeling that incorporates information from histology, morphometry, and immunohisto- chemistry using samples from intrinsic versus extrinsic asthmatics as well as appropriate controls (including those with other lung diseases).|
|2.||To what extent is this remodeling process a normal response to an ab-|
|normal injury, or is the response itself abnormal?|
|3.||What perpetuates the remodeling process?|
|4.||Does the heterogeneity in time and extent reflect genetic variation or|
|5.||How early does remodeling begin?|
|6.||How does remodeling progress?|
|7.||Is remodeling reversible?|
|8.||Can the remodeling process be altered and do any of the current anti-|
|inflammatory strategies make any difference to the long-term outcome?|
|10.||Can a useful and relevant marker (or markers) of remodeling be found?|
|1.||Ciba Guest SymposiumTerminology, definitions and classification of chronic pulmonary emphysema and related conditions. Thorax141959286299|
|2.||WHO/NHLBI Workshop Report. 1995. Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD. Publication No. 95-3659.|
|3.||Chanez P., Vignola A., O'Shaugnessy T., Enander I., Li D., Jeffery P., Bousquet J.Corticosteroid reversibility in COPD is related to features of asthma. Am. J. Respir. Crit. Care Med.155199715291534|
|4.||Godard P., Chaintreuil J., Damon M., Coupe M., Flandre O., Crastes-de-Paulet A., Michel F. B.Functional assessment of alveolar macrophages: comparison of cells from asthmatics and normal subjects. J. Allergy Clin. Immunol.7019828893|
|5.||Jeffery P.Bronchial biopsies and airway inflammation. Eur. Respir. J.9199615831587|
|6.||Maestrelli P., Saetta M., Di-Stefano A., Calcagni P. G., Turato G., Ruggieri M. P., Roggeri A., Mapp C. E., Fabbri L. M.Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am. J. Respir. Crit. Care Med.152199519261931|
|7.||Ellis A.The pathological anatomy of bronchial asthma. Am. J. Med. Sci.1361908407429|
|8.||Holgate S. T.Asthma genetics: waiting to exhale. Nat. Genet.151997227229|
|9.||Platts-Mills T., Wheatley L.The role of allergy and atopy in asthma. Curr. Opin. Pulmon. Med.219962934|
|10.||Bentley A. M., Durham S. R., Kay A. B.Comparison of the immunopathology of extrinsic, intrinsic and occupational asthma. J. Investig. Allergol. Clin. Immunol.41994222232|
|11.||Humbert M., Durham S. R., Ying S., Kimmitt P., Barkans J., Assoufi B., Pfister R., Menz G., Robinson D.S., Kay A. B., Corrigan C. J.IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am. J. Respir. Crit. Care Med.154199614971504|
|12.||Humbert M., Grant J. A., Taborda-Barata L., Durham S. R., Pfister R., Menz G., Barkans J., Ying S., Kay A. B.High-affinity IgE receptor (Fcɛ RI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am. J. Respir. Crit. Care Med.153199619311937|
|13.||Expert Panel Report 2. 1997. Guidelines for the diagnosis and management of asthma. NIH Publication No. 97-4051.|
|14.||Management of Pediatric AsthmaSymposium proceedings. London, England, November 18, 1996. Pediatr. Pulmonol. Suppl.151997158|
|15.||Busse W. W., Gern J. E.Viruses in asthma. J. Allergy Clin. Immunol.1001997147150|
|16.||Wardlaw A. J.The role of air pollution in asthma. Clin. Exp. Allergy2319938196|
|17.||Murray J. J., Tonnel A. B., Brash A. R., Roberts L. D., Gosset P., Workman R., Capron A., Oates J. A.Prostaglandin D2 is released during acute allergic bronchospasm in man. Trans. Assoc. Am. Physicians981985275280|
|18.||Liu M. C., Hubbard W. C., Proud D., Stealey B. A., Galli S. J., Kagey-Sobotka A., Bleecker E. R., Lichtenstein L. M.Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics: cellular, mediator, and permeability changes. Am. Rev. Respir. Dis.14419915158|
|19.||Tonnel A. B., Joseph M., Gosset P., Fournier E., Capron A.Stimulation of alveolar macrophages in asthmatic patients after local provocation test. Lancet1198314061408|
|20.||Calhoun W. J., Reed H. E., Moest D. R., Stevens C. A.Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. Am. Rev. Respir. Dis.1451992317325|
|21.||Gounni A. S., Lamkhioued B., Ochiai K., Tanaka Y., Delaporte E., Capron A., Kinet J. P., Capron M.High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature3671994183186|
|22.||Jarjour N., Calhoun W., Becky-Wells E., Gleich G., Schwartz L., Busse W.The immediate and late-phase allergic response to segmental bronchopulmonary provocation in asthma. Am. J. Respir. Crit. Care Med.155199715151521|
|23.||Wenzel S. E., Westcott J. Y., Smith H. R., Larsen G. L.Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups: an alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am. Rev. Respir. Dis.1391989450457|
|24.||Persson C. G., Andersson M., Greiff L., Svensson C., Erjefalt J. S., Sundler F., Wollmer P., Alkner U., Erjefalt I., Gustafsson B., Linden M., Nilsson M.Airway permeability. Clin. Exp. Allergy251995807814|
|25.||Greiff L., Erjefalt I., Svensson C., Wollmer P., Alkner U., Andersson M., Persson C. G.Plasma exudation and solute absorption across the airway mucosa. Clin. Physiol.131993219233|
|26.||Van-Vyve T., Chanez P., Bernard A., Bousquet J., Godard P., Lauwerijs R., Sibille Y.Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects. J. Allergy Clin. Immunol.9519956068|
|27.||Wanner A., Salathe M., O'Riordan T. G.Mucociliary clearance in the airways. Am. J. Respir. Crit. Care Med.154199618681902|
|28.||De Monchy J. G., Kauffman H. F., Venge P., Koeter G. H., Jansen H. M., Sluiter H. J., De Vries K.Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis.1311985373376|
|29.||Robinson D., Hamid Q., Bentley A., Ying S., Kay A. B., Durham S. R.Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J. Allergy Clin. Immunol.921993313324|
|30.||Guo C. B., Liu M. C., Galli S. J., Bochner B. S., Kagey-Sobotka A., Lichtenstein L. M.Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am. J. Respir. Cell Mol. Biol.101994384390|
|31.||Koh Y. Y., Dupuis R., Pollice M., Albertine K. H., Fish J. E., Peters S. P.Neutrophils recruited to the lungs of humans by segmental antigen challenge display a reduced chemotactic response to leukotriene B4. Am. J. Respir. Cell Mol. Biol.81993493499|
|32.||Montefort S., Gratziou C., Goulding D., Polosa R., Haskard D. O., Howarth P. H., Holgate S. T., Carroll M. P.Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte– endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. J. Clin. Invest.93199414111421|
|33.||Calhoun W. J., Jarjour N. N., Gleich G. J., Stevens C. A., Busse W. W.Increased airway inflammation with segmental versus aerosol antigen challenge. Am. Rev. Respir. Dis.147199314651471|
|34.||Gratziou C., Carroll M., Montefort S., Teran L., Howarth P. H., Holgate S. T.Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. Am. J. Respir. Crit. Care Med.1531996515520|
|35.||Lassalle P., Gosset P., Delneste Y., Tsicopoulos A., Capron A., Joseph M., Tonnel A. B.Modulation of adhesion molecule expression on endothelial cells during the late asthmatic reaction: role of macrophage-derived tumour necrosis factor-alpha. Clin. Exp. Immunol941993105110|
|36.||Georas S. N., Liu M. C., Newman W., Beall L. D., Stealey B. A., Bochner B. S.Altered adhesion molecule expression and endothelial cell activation accompany the recruitment of human granulocytes to the lung after segmental antigen challenge. Am. J. Respir. Cell Mol. Biol.71992261269|
|37.||Bentley A. M., Durham S. R., Robinson D. S., Menz G., Storz C., Cromwell O., Kay A. B., Wardlaw A. J.Expression of endothelial and leukocyte adhesion molecules interacellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma. J. Allergy Clin. Immunol.921993857868|
|38.||Smith H. R., Larsen G. L., Cherniack R. M., Wenzel S. E., Voelkel N. F., Westcott J. Y., Bethel R. A.Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsiveness. J. Allergy Clin. Immunol.89199210761084|
|39.||Zangrilli J. G., Shaver J. R., Cirelli R. A., Cho S. K., Garlisi C. G., Falcone A., Cuss F. M., Fish J. E., Peters S. P.sVCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late-phase response. Am. J. Respir. Crit. Care Med.151199513461353|
|40.||Kay A. B.“Helper” (CD4+) T cells and eosinophils in allergy and asthma. Am. Rev. Respir. Dis.1451992S22S26|
|41.||Bradding P., Roberts J. A., Britten K. M., Montefort S., Djukanovic R., Mueller R., Heusser C. H., Howarth P. H., Holgate S. T.Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol.101994471480|
|42.||Bentley A. M., Meng Q., Robinson D. S., Hamid Q., Kay A. B., Durham S. R.Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am. J. Respir. Cell Mol. Biol.819933542|
|43.||Cockcroft D. W., Murdock K. Y.Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J. Allergy Clin. Immunol.791987734740|
|44.||Fabbri L. M., Saetta M., Picotti G., Mapp C. E.Late asthmatic reactions, airway inflammation and chronic asthma in toluene-diisocyanate-sensitized subjects. Respiration119911821|
|45.||Holgate S. T.The 1992 Cournand Lecture. Asthma: past, present and future. Eur. Respir. J.6199315071520|
|46.||Bochner B. S., Undem B. J., Lichtenstein L. M.Immunological aspects of allergic asthma. Annu. Rev. Immunol.121994295335|
|47.||Robinson D. S., Damia R., Zeibecoglou K., Molet S., North J., Yamada T., Barry A., Kay, Hamid Q.CD34(+)/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. Am. J. Respir. Cell Mol. Biol.201999913|
|48.||Sehmi R., Howie K., Sutherland D. R., Schragge W., O'Byrne P. M., Denburg J. A.Increased levels of CD34+ hemopoietic progenitor cells in atopic subjects. Am. J. Respir. Cell Mol. Biol.151996645655|
|49.||Denburg J. A., Inman M. D., Leber B., Sehmi R., O'Byrne P. M.The role of the bone marrow in allergy and asthma. Allergy511996141148|
|50.||Demoly P., Simony-Lafontaine J., Chanez P., Pujol J. L., Lequeux N., Michel F. B., Bousquet J.Cell proliferation in the bronchial mucosa of asthmatics and chronic bronchitics. Am. J. Respir. Crit. Care Med.1501994214217|
|51.||Granger D. N., Kubes P.The microcirculation and inflammation: modulation of leukocyte–endothelial cell adhesion. J. Leukoc. Biol.551994662675|
|52.||Bochner B., Schleimer R.The role of adhesion molecules in human eosinophil and basophil recruitment. J. Allergy Clin. Immunol.941994427439|
|53.||Neeley S. P., Hamann K. J., White S. R., Baranowski S. L., Burch R. A., Leff A.R.Selective regulation of expression of surface adhesion molecules Mac-1, L-selectin, and VLA-4 on human eosinophils and neutrophils. Am. J. Respir. Cell Mol. Biol.81993633639|
|54.||Ohkawara Y., Yamauchi K., Maruyama N., Hoshi H., Ohno I., Honma M., Tanno Y., Tamura G., Shirato K., Ohtani H.In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: in vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. Am. J. Respir. Cell Mol. Biol.121995412|
|55.||Wardlaw A., Bentley A. M., Menz G., Storz C., Durham S. R., Kay A. B.Expression of adhesion molecules ICAM-1 and ELAM-1 in the bronchial mucosa in asthma (abstract). J. Allergy Clin. Immunol.891992164|
|56.||Fukuda T., Fukushima Y., Numao T., Ando N., Arima M., Nakajima H., Sagara H., Adachi T., Motojima S., Makino S.Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am. J. Respir. Cell Mol. Biol.1419968494|
|57.||Nagata M., Sedgwick J. B., Busse W. W.Differential effects of granulocyte-macrophage colony-stimulating factor on eosinophil and neutrophil superoxide anion generation. J. Immunol.155199549484954|
|58.||Sur S., Gleich G. J., Swanson M. C., Bartemes K. R., Broide D. H.Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. J. Allergy Clin. Immunol.961995661668|
|59.||Lopez A. F., Sanderson C. J., Gamble J. R., Campbell H. D., Young I. G., Vadas M. A.Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med.1671988219224|
|60.||Sedgwick J. B., Quan S. F., Calhoun W. J., Busse W. W.Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: comparison with airway eosinophils. J. Allergy Clin. Immunol.961995375385|
|61.||Alam R., Stafford S., Forsythe P., Harrison R., Faubion D., Lett-Brown M. A., Grant J. A.RANTES is a chemotactic and activating factor for human eosinophils. J. Immunol.150199334423448|
|62.||Teran L. M., Noso N., Carroll M., Davies D. E., Holgate S., Schroder J. M.Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J. Immunol.157199618061812|
|63.||Garcia-Zepeda E. A., Rothenberg M. E., Ownbey R. T., Celestin J., Leder P., Luster A. D.Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat. Med.21996449456|
|64.||Elsner J., Hochstetter R., Kimmig D., Kapp A.Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur. J. Immunol.26199619191925|
|65.||Sallusto F., Mackay C. R., Lanzavecchia A.Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science277199720052007|
|66.||Holgate S. T., Bodey K. S., Janezic A., Frew A. J., Kaplan A. P., Teran L. M.Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. J. Respir. Crit. Care Med.156199713771383|
|67.||Cruikshank W. W., Long A., Tarpy R. E., Kornfeld H., Carroll M. P., Teran L., Holgate S. T., Center D. M.Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am. J. Respir. Cell Mol. Biol.131995738747|
|68.||Nelson H. S.Beta-adrenergic bronchodilators. N. Engl. J. Med.3331995499506|
|69.||Drazen J. M., Israel E., Boushey H. A., Chinchilli V. M., Fahy J. V., Fish J. E., Lazarus S. C., Lemanske R. F., Martin R. J., Peters S. P., Sorkness C., Szefler S. J.Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network [see comments]. N. Engl. J. Med.3351996841847|
|70.||O'Byrne P. M., Kerstjens H. A.Inhaled beta 2-agonists in the treatment of asthma [Editorial; comment]. N. Engl. J. Med.3351996886888|
|71.||Busse W. W.Long-and short-acting beta 2-adrenergic agonists: effects on airway function in patients with asthma. Arch. Intern. Med.156199615141520|
|72.||Britton M. G., Earnshaw J. S., Palmer J. B.A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. Eur. Respir. J.5199210621067|
|73.||Arvidsson P., Larsson S., Lofdahl C. G., Melander B., Svedmyr N., Wahlander L.Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur. Respir. J.4199111681173|
|74.||Reihsaus E., Innis M., MacIntyre N., Liggett S. B.Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol.81993334339|
|75.||Green S. A., Turki J., Bejarano P., Hall I. P., Liggett S. B.Influence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol.1319952533|
|76.||Bousquet J., Chanez P., Lacoste J. Y., Barneon G., Ghavanian N., Enander I., Venge P., Ahlstedt S., Simony-Lafontaine J., Godard P., Michel F. B.Eosinophilic inflammation in asthma. N. Engl. J. Med.323199010331039|
|77.||Vignola A. M., Campbell A. M., Chanez P., Bousquet J., Paul-Lacoste P., Michel F. B., Godard P.HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis. Am. Rev. Respir. Dis.1481993689694|
|78.||Haley K. J., Drazen J. M.Inflammation and airway function in asthma: what you see is not necessarily what you get [Editorial; comment]. Am. J. Respir. Crit. Care Med.157199813|
|79.||Wallaert B., Desreumaux P., Copin M. C., Tillie I., Benard A., Colombel J.F., Gosselin B., Tonnel A. B., Janin A.Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. J. Exp. Med.182199518971904|
|80.||Kraft M., Djukanovic R., Wilson S., Holgate S., Martin R.Alveolar tissue inflammation in asthma. Am. J. Respir. Crit. Care Med.154199615051511|
|81.||Carroll N., Cooke C., James A.The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur. Respir. J.101997292300|
|82.||Faul J., Thorney V., Leonard C., Burke C., Farmer J., Horne S., Poulter L.The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur. Respir. J.101997301308|
|83.||Haslett C., Savill J. S., Whyte M. K., Stern M., Dransfield I., Meagher L. C.Granulocyte apoptosis and the control of inflammation. Philos. Trans. R. Soc. Lond. B Biol. Sci.3451994327333|
|84.||White E.Life, death, and the pursuit of apoptosis. Genes Dev.101996115|
|85.||Ohnishi T., Sur S., Collins D. S., Fish J. E., Gleich G. J., Peters S. P.Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J. Allergy Clin. Immunol.921993607615|
|86.||Woolley K. L., Gibson P. G., Carty K., Wilson A. J., Twaddell S. H., Woolley M. J.Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med.1541996237243|
|87.||Walsh G.Mechanisms of human eosinophil survival and apoptosis. Clin. Exp. Allergy271997482487|
|88.||Canonica G., Ciprandi G.Adhesion molecules of the allergic inflammation: recent insight on their functional role. Allergy491994135141|
|89.||Simon H. U., Blaser K.Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol. Today1619955355|
|90.||Sousa A. R., Poston R. N., Lane S. J., Nakhosteen J. A., Lee T. H.Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am. Rev. Respir. Dis.147199315571561|
|91.||Hamid Q., Azzawi M., Ying S., Moqbel R., Wardlaw A. J., Corrigan C. J., Bradley B., Durham S. R., Collins J. V., Jeffery P. K., Quint D. J., Kay A. B.Interleukin-5 mRNA in mucosal bronchial biopsies from asthmatic subjects. Int. Arch. Allergy Appl. Immunol.941991169170|
|92.||Woolley K. L., Adelroth E., Woolley M. J., Ellis R., Jordana M., O'Byrne P. M.Granulocyte-macrophage colony-stimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma. Eur. Respir. J.7199415761584|
|93.||Robinson D. S., Ying S., Bentley A. M., Meng Q., North J., Durham S. R., Kay A. B., Hamid Q.Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J. Allergy Clin. Immunol.921993397403|
|94.||Humbert M., Ying S., Corrigan C., Menz G., Barkans J., Pfister R., Meng Q., Van-Damme J., Opdenakker G., Durham S. R., Kay A. B.Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am. J. Respir. Cell Mol. Biol.16199718|
|95.||Berkman N., Krishnan V. L., Gilbey T., Newton R., O'Connor B., Barnes P. J., Chung K. F.Expression of RANTES mRNA and protein in airways of patients with mild asthma. Am. J. Respir. Crit. Care Med.154199618041811|
|96.||Anderson G. P.Resolution of chronic inflammation by therapeutic induction of apoptosis. Trends Pharmacol. Sci.171996438442|
|97.||Her E., Frazer J., Austen K. F., Owen W.Eosinophil hematopoietins antagonize the programmed cell death of eosinophils: cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell–conditioned medium. J. Clin. Invest.88199119821987|
|98.||Wallen N., Kita H., Weiler D., Gleich G. J.Glucocorticoids inhibit cytokine-mediated eosinophil survival. J. Immunol.147199134903495|
|99.||Meagher L. C., Cousin J. M., Seckl J. R., Haslett C.Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol.156199644224428|
|100.||Adachi T., Motojima S., Hirata A., Fukuda T., Kihara N., Kosaku A., Ohtake H., Makino S.Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J. Allergy Clin. Immunol.981996S207S215|
|101.||Mentz F., Merle-Beral H., Ouaaz F., Binet J. L.Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides. Br. J. Haematol.901995957959|
|102.||Jeffery P. K.Pathology of asthma. Br. Med. Bull.4819922339|
|103.||Schwartz L. B.Cellular inflammation in asthma: neutral proteases of mast cells. Am. Rev. Respir. Dis.1451992S18S21|
|104.||Henderson W.The role of leukotrienes in inflammation. Ann. Intern. Med.1211994684697|
|105.||Racke K., Brunn G., Wessler I.Nitric oxide and asthmatic inflammation. Immunol. Today171996147148|
|106.||Barnes P.NO or no NO in asthma? Thorax511996218220|
|107.||Gleich G. J., Adolphson C. R., Leiferman K. M.The biology of the eosinophilic leukocyte. Annu. Rev. Med.44199385101|
|108.||Holgate S.Mediator and cytokine mechanisms in asthma. Thorax481993103109|
|109.||Drazen J. M., Arm J. P., Austen K. F.Sorting out the cytokines of asthma. J. Exp. Med.183199615|
|110.||Shah A., Church M. K., Holgate S. T.Tumour necrosis factor alpha: a potential mediator of asthma. Clin. Exp. Allergy25199510381044|
|111.||Maestrelli P., di Stefano A., Occari P., Turato G., Milani G., Pivirotto F., Mapp C. E., Fabbri L. M., Saetta M.Cytokines in the airway mucosa of subjects with asthma induced by toluene diisocyanate. Am. J. Respir. Crit. Care Med.1511995607612|
|112.||Jarjour N. N., Busse W. W.Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma. Am. J. Respir. Crit. Care Med.152199514741477|
|113.||Mueller R., Chanez P., Campbell A. M., Bousquet J., Heusser C., Bullock G. R.Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir. Med.9019967985|
|114.||Laitinen L. A., Heino M., Laitinen A., Kava T., Haahtela T.Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am. Rev. Respir. Dis.1311985599606|
|115.||Montefort S., Djukanovic R., Holgate S. T., Roche W. R.Ciliated cell damage in the bronchial epithelium of asthmatics and non-asthmatics. Clin. Exp. Allergy231993185189|
|116.||Campbell A. M., Chanez P., Vignola A. M., Bousquet J., Couret I., Michel F. B., Godard P.Functional characteristics of bronchial epithelium obtained by brushing from asthmatic and normal subjects. Am. Rev. Respir. Dis.1471993529534|
|117.||Montefort S., Herbert C. A., Robinson C., Holgate S. T.The bronchial epithelium as a target for inflammatory attack in asthma. Clin. Exp. Allergy221992511520|
|118.||Persson C. G.Epithelial cells: barrier functions and shedding-restitution mechanisms. Am. J. Respir. Crit. Care Med.1531996S9S10|
|119.||Gleich G. J., Frigas E., Loegering D. A., Wassom D. L., Steinmuller D.Cytotoxic properties of the eosinophil major basic protein. J. Immunol.123197929252927|
|120.||Takafuji S., Ohtoshi T., Takizawa H., Tadokoro K., Ito K.Eosinophil degranulation in the presence of bronchial epithelial cells: effect of cytokines and role of adhesion. J. Immunol.156199639803985|
|121.||Kips J. C., Tavernier J. H., Joos G. F., Peleman R. A., Pauwels R. A.The potential role of tumour necrosis factor alpha in asthma. Clin. Exp. Allergy231993247250|
|122.||Rickard K. A., Taylor J., Rennard S. I.Observations of development of resistance to detachment of cultured bovine bronchial epithelial cells in response to protease treatment. Am. J. Respir. Cell Mol. Biol.61992414420|
|123.||Mautino G., Oliver N., Chanez P., Bousquet J., Capony F.Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am. J. Respir. Cell Mol. Biol.171997583591|
|124.||Lackie P. M., Baker J. E., Gunthert U., Holgate S. T.Expression of CD44 isoforms is increased in the airway epithelium of asthmatic subjects. Am. J. Respir. Cell Mol. Biol.1619971422|
|125.||Jeffery P. K., Wardlaw A. J., Nelson F. C., Collins J. V., Kay A. B.Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am. Rev. Respir. Dis.140198917451753|
|126.||Ohashi Y., Motojima S., Fukuda T., Makino S.Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma [see comments]. Am. Rev. Respir. Dis.145199214691476|
|127.||Inoue K., Sakai Y., Homma I.An ubiquitous modulating function of rabbit tracheal epithelium: degradation of tachykinins. Br. J. Pharmacol.1051992393399|
|128.||Sparrow M. P., Mitchell H. W.Modulation by the epithelium of the extent of bronchial narrowing produced by substances perfused through the lumen. Br. J. Pharmacol.103199111601164|
|129.||Rabe K. F., Dent G., Magnussen H.Hydrogen peroxide contracts human airways in vitro: role of epithelium. Am. J. Physiol.2691995L332L338|
|130.||Lilly C. M., Drazen J. M., Shore S. A.Peptidase modulation of airway effects of neuropeptides. Proc. Soc. Exp. Biol. Med.2031993388404|
|131.||Knight D. A., Stewart G. A., Lai M. L., Thompson P. J.Epithelium-derived inhibitory prostaglandins modulate human bronchial smooth muscle responses to histamine. Eur. J. Pharmacol.2721995111|
|132.||Hamid Q., Springall D. R., Riveros-Moreno V., Chanez P., Howarth P., Redington A., Bousquet J., Godard P., Holgate S., Polak J. M.Induction of nitric oxide synthase in asthma. Lancet342199315101513|
|133.||Cromwell O., Hamid Q., Corrigan C. J., Barkans J., Meng Q., Collins P. D., Kay A. B.Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha. Immunology771992330337|
|134.||Lilly C. M., Nakamura H., Kesselman H., Nagler-Anderson C., Asano K., Garcia-Zepeda E. A., Rothenberg M. E., Drazen J. M., Luster A. D.Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest.99199717671773|
|135.||Cambrey A. D., Kwon O. J., Gray A. J., Harrison N. K., Yacoub M., Barnes P. J., Laurent G. J., Chung K. F.Insulin-like growth factor I is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells. Clin. Sci. Colch.891995611617|
|136.||Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., Alitalo K.Vascular endothelial growth factor is induced in response to transforming growth factor–beta in fibroblastic and epithelial cells. J. Biol. Chem.269199462716274|
|137.||Harkonen E., Virtanen I., Linnala A., Laitinen L. L., Kinnula V. L.Modulation of fibronectin and tenascin production in human bronchial epithelial cells by inflammatory cytokines in vitro. Am. J. Respir. Cell Mol. Biol.131995109115|
|138.||Yao P. M., Buhler J. M., d'Ortho M. P., Lebargy F., Delclaux C., Harf A., Lafuma C.Expression of matrix metalloproteinase gelatinases A and B by cultured epithelial cells from human bronchial explants. J. Biol. Chem.27119961558015589|
|139.||Nakamura Y., Tate L., Ertl R. F., Kawamoto M., Mio T., Adachi Y., Romberger D. J., Koizumi S., Gossman G., Robbins R. A., Spurzem J. R., Rennarol S. I.Bronchial epithelial cells regulate fibroblast proliferation. Am. J. Physiol.2691995L377L387|
|140.||Bradding P., Redington A. E., Djukanovic R., Conrad D. J., Holgate S. T.15-lipoxygenase immunoreactivity in normal and in asthmatic airways. Am. J. Respir. Crit. Care Med.151199512011204|
|141.||Montefort S., Baker J., Roche W. R., Holgate S. T.The distribution of adhesive mechanisms in the normal bronchial epithelium. Eur. Respir. J.6199312571263|
|142.||Gosset P., Tillie-Leblond I., Janin A., Marquette C. H., Copin M. C., Wallaert B., Tonnel A. B.Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients. Int. Arch. Allergy Immunol.10619956977|
|143.||Springall D. R., Howarth P. H., Counihan H., Djukanovic R., Holgate S. T., Polak J. M.Endothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet3371991697701|
|144.||Wang J. H., Trigg C. J., Devalia J. L., Jordan S., Davies R. J.Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma. J. Allergy Clin. Immunol.94199410251034|
|145.||Sousa A., Trigg C., Lane S., Hawksworth R., Nakhosteen J., Poston R., Lee T.Effect of inhaled glucocorticoids on IL-1β and IL-1 receptor antagonist (IL-1ra) expression in athmatic bronchial epithelium. Thorax521997407411|
|146.||Wang J. H., Devalia J. L., Xia C., Sapsford R. J., Davies R. J.Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Am. J. Respir. Cell Mol. Biol.1419962735|
|147.||Campbell A. M., Vignola A. M., Chanez P., Godard P., Bousquet J.Low-affinity receptor for IgE on human bronchial epithelial cells in asthma. Immunology821994506508|
|148.||Devalia J. L., Campbell A. M., Sapsford R. J., Rusznak C., Quint D., Godard P., Bousquet J., Davies R. J.Effect of nitrogen dioxide on synthesis of inflammatory cytokines expressed by human bronchial epithelial cells in vitro. Am. J. Respir. Cell Mol. Biol.91993271278|
|149.||Vignola A. M., Campbell A. M., Chanez P., Lacoste P., Michel F. B., Godard P., Bousquet J.Activation by histamine of bronchial epithelial cells from nonasthmatic subjects. Am. J. Respir. Cell Mol. Biol.91993411417|
|150.||Shoji S., Ertl R. F., Linder J., Romberger D. J., Rennard S. I.Bronchial epithelial cells produce chemotactic activity for bronchial epithelial cells: possible role for fibronectin in airway repair. Am. Rev. Respir. Dis.1411990218225|
|151.||Levine S. J.Bronchial epithelial cell–cytokine interactions in airway inflammation. J. Investig. Med.431995241249|
|152.||Chihara J., Urayama O., Tsuda A., Kakazu T., Higashimoto I., Yamada H.Eosinophil cationic protein induces insulin-like growth factor I receptor expression on bronchial epithelial cells. Int. Arch. Allergy Immunol.119964345|
|153.||Jakowlew S. B., Mariano J. M., You L., Mathias A.Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells. Biochim. Biophys. Acta13531997157170|
|154.||Nakamura Y., Tate L., Ertl R. F., Kawamoto M., Mio T., Adachi Y., Romberger D. J., Koizumi S., Gossman G., Robbins R. A., Spurzem J. R., Rennarol S. I.Bronchial epithelial cells regulate fibroblast proliferation. Am. J. Physiol.2691995L377L387|
|155.||Yao P. M., Maitre B., Delacourt C., Buhler J. M., Harf A., Lafuma C.Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNF-alpha. Am. J. Physiol.2731997L866L874|
|156.||Gibson P. G., Allen C. J., Yang J. P., Wong B. J., Dolovich J., Denburg J., Hargreave F. E.Intraepithelial mast cells in allergic and nonallergic asthma: assessment using bronchial brushings. Am. Rev. Respir. Dis.14819938086|
|157.||Poston R. N., Chanez P., Lacoste J. Y., Litchfield T., Lee T. H., Bousquet J.Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi. Am. Rev. Respir. Dis.1451992918921|
|158.||Pesci A., Foresi A., Bertorelli G., Chetta A., Oliveri D.Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and normal subjects. Am. Rev. Respir. Dis.1471993684689|
|159.||Blyth D. I., Pedrick M. S., Savage T. J., Hessel E. M., Fattah D.Lung inflammation and epithelial changes in a murine model of atopic asthma. Am. J. Respir. Cell Mol. Biol.141996425438|
|160.||Lacoste J. Y., Bousquet J., Chanez P., Van Vyve T., Simony-Lafontaine J., Lequeu N., Vic P., Enander I., Godard P., Michel F. B.Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol.921993537548|
|161.||Broide D. H., Gleich G. J., Cuomo A. J., Coburn D. A., Federman E. C., Schwartz L. B., Wasserman S. I.Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J. Allergy Clin. Immunol.881991637648|
|162.||Laitinen L. A., Laitinen A., Heino M., Haahtela T.Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am. Rev. Respir. Dis.1431991423427|
|163.||Bradley B. L., Azzawi M., Jacobson M., Assoufi B., Collins J. V., Irani A. M., Schwartz L. B., Durham S. R., Jeffery P. K., Kay A. B.Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol.881991661674|
|164.||Azzawi M., Johnston P. W., Majumdar S., Kay A. B., Jeffery P. K.T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am. Rev. Respir. Dis.145199214771482|
|165.||Azzawi M., Bradley B., Jeffery P. K., Frew A. J., Wardlaw A. J., Knowles G., Assoufi B., Collins J. V., Durham S., Kay A. B.Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am. Rev. Respir. Dis.142199014071413|
|166.||Shaver J. R., Zangrilli J. G., Cho S. K., Cirelli R. A., Pollice M., Hastie A. T., Fish J. E., Peters S. P.Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. Am. J. Respir. Crit. Care Med.1551997442448|
|167.||Kroegel C., Liu M. C., Hubbard W. C., Lichtenstein L. M., Bochner B. S.Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. J. Allergy Clin. Immunol.931994725734|
|168.||Busse W. W., Sedgwick J. B.Eosinophil eicosanoid relations in allergic inflammation of the airways. Adv. Prostaglandin Thromboxane Leukot. Res.221994241249|
|169.||Ying S., Durham S. R., Corrigan C. J., Hamid Q., Kay A. B.Phenotype of cells expressing mRNA for Th2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am. J. Respir. Cell Mol. Biol.121995477487|
|170.||Broide D. H., Paine M. M., Firestein G. S.Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J. Clin. Invest.90199214141424|
|171.||Weller P. F.The immunobiology of eosinophils. N. Engl. J. Med.324199111101118|
|172.||Rabe K. F., Munoz N. M., Vita A. J., Morton B. E., Magnussen H., Leff A. R.Contraction of human bronchial smooth muscle caused by activated human eosinophils. Am. J. Physiol.2671994L326334|
|173.||Collins D. S., Dupuis R., Gleich G. J., Bartemes K. R., Koh Y. Y., Pollice M., Albertine K. H., Fish J. E., Peters S. P.Immunoglobulin E-mediated increase in vascular permeability correlates with eosinophilic inflammation. Am. Rev. Respir. Dis.1471993677683|
|174.||Leff A. R.Inflammatory mediation of airway hyperresponsiveness by peripheral blood granulocytes: the case for the eosinophil. Chest106199412021208|
|175.||Ohno I., Lea R. G., Flanders K. C., Clark D. A., Banwatt D., Dolovich J., Denburg J., Harley C. B., Gauldie J., Jordana M.Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J. Clin. Invest.89199216621668|
|176.||Walz T. M., Nishikawa B. K., Malm C., Wasteson A.Production of transforming growth factor alpha by normal human blood eosinophils. Leukemia7199315311537|
|177.||Lungarella G., Menegazzi R., Gardi C., Spessotto P., de Santi M. M., Bertoncin P., Patriarca P., Calzoni P., Zabucchi G.Identification of elastase in human eosinophils: immunolocalization, isolation, and partial characterization. Arch. Biochem. Biophys.2921992128135|
|178.||Ohno I., Ohtani H., Nitta Y., Suzuki J., Hoshi H., Honma M., Isoyama S., Tanno Y., Tamura G., Yamauchi K., Nagura H., Shirato K.Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol.161997212219|
|179.||Pincus S. H., Ramesh K. S., Wyler D. J.Eosinophils stimulate fibroblast DNA synthesis. Blood701987572574|
|180.||Hall F. C., Walport M. J.Hypereosinophilic syndromes: association with vasculitis, fibrosis and autoimmunity [Editorial; comment]. Clin. Exp. Allergy231993542547|
|181.||Schlick W.Current issues in the assessment of interstitial lung disease. Monaldi Arch. Chest Dis.481993237244|
|182.||Ottesen E. A., Nutman T. B.Tropical pulmonary eosinophilia. Annu. Rev. Med.431992417424|
|183.||Noguchi H., Kephart G. M., Colby T. V., Gleich G. J.Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am. J. Pathol.1401992521528|
|184.||Bentley A. M., Maestrelli P., Saetta M., Fabbri L. M., Robinson D. S., Bradley B. L., Jeffery P. K., Durham S. R., Kay A. B.Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J. Allergy Clin. Immunol.891992821829|
|185.||Saetta M., Di Stefano A., Maestrelli P., De Marzo N., Milani G. F., Pivirotto F., Mapp C. E., Fabbri L. M.Airway mucosal inflammation in occupational asthma induced by toluene diisocyanate. Am. Rev. Respir. Dis.1451992160168|
|186.||Corrigan C. J., Hamid Q., North J., Barkans J., Moqbel R., Durham S., Gemou-Engesaeth V., Kay A. B.Peripheral blood CD4 but not CD8 T-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy. Am. J. Respir. Cell Mol. Biol.121995567578|
|187.||Walker C., Kaegi M. K., Braun P., Blaser K.Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J. Allergy Clin. Immunol.881991935942|
|188.||Robinson D. S., Bentley A. M., Hartnell A., Kay A. B., Durham S. R.Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax4819932632|
|189.||Saetta M., Di Stefano A., Maestrelli P., Ferraresso A., Drigo R., Potena A., Ciaccia A., Fabbri L. M.Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am. Rev. Respir. Dis.1471993301306|
|190.||Di Stefano A., Turato G., Maestrelli P., Mapp C. E., Ruggieri M. P., Roggeri A., Boschetto P., Fabbri L. M., Saetta M.Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am. J. Respir. Crit. Care Med.1531996629632|
|191.||O'Shaughnessy T. C., Ansari T. W., Barnes N. C., Jeffery P. K.Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am. J. Respir. Crit. Care Med.1551997852857|
|192.||Robinson D. S., Hamid Q., Ying S., Tsicopoulos A., Barkans J., Bentley A. M., Corrigan C., Durham S. R., Kay A. B.Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med.3261992298304|
|193.||Del Prete G. F., De Carli M., D'Elios M. M., Maestrelli P., Ricci M., Fabbri L., Romagnani S.Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur. J. Immunol.23199314451449|
|194.||Pene J., Lagier B., Rivier A., Chanez P., Vendrell J. P., Bousquet J.Phenotype of T cell clones obtained from bronchial biopsies and peripheral blood from three asthmatics. Cell. Biol. Int.171993353357|
|195.||Krug N., Madden J., Redington A. E., Lackie P., Djukanovic R., Schauer U., Holgate S. T., Frew A. J., Howarth P. H.T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma [see comments]. Am. J. Respir. Cell Mol. Biol.141996319326|
|196.||Walker C., Bode E., Boer L., Hansel T. T., Blaser K., Virchow J.Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am. Rev. Respir. Dis.1461992109115|
|197.||Djukanovic R., Wilson J. W., Britten K. M., Wilson S. J., Walls A. F., Roche W. R., Howarth P. H., Holgate S. T.Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am. Rev. Respir. Dis.1421990863871|
|198.||Koshino T., Arai Y., Miyamoto Y., Sano Y., Takaishi T., Hirai K., Ito K., Morita Y.Mast cell and basophil number in the airway correlate with the bronchial responsiveness of asthmatics. Int. Arch. Allergy Immunol.1071995378379|
|199.||Beasley R., Roche W. R., Roberts J. A., Holgate S. T.Cellular events in the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. Dis.1391989806817|
|200.||Synek M., Anto J. M., Beasley R., Frew A. J., Holloway L., Lampe F. C., Lloreta J. L., Sunyer J., Thornton A., Holgate S. T.Immunopathology of fatal soybean dust-induced asthma. Eur. Respir. J.919965457|
|201.||Tomioka M., Ida S., Shindoh Y., Ishihara T., Takishima T.Mast cells in bronchoalveolar lumen of patients with bronchial asthma. Am. Rev. Respir. Dis.129198410001005|
|202.||Casale T. B., Marom Z.Mast cells and asthma: the role of mast cell mediators in the pathogenesis of allergic asthma. Ann. Allergy51198326|
|203.||Jarjour N. N., Calhoun W. J., Schwartz L. B., Busse W. W.Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am. Rev. Respir. Dis.14419918387|
|204.||Bousquet J., Chanez P., Lacoste J. Y., Enander I., Venge P., Peterson C., Ahlstedt S., Michel F. B., Godard P.Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. J. Allergy Clin. Immunol.881991649660|
|205.||Imamura T., Dubin A., Moore W., Tanaka R., Travis J.Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab. Invest.741996861870|
|206.||Johnson P. R., Ammit A. J., Carlin S. M., Armour C. L., Caughey G. H., Black J. L.Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur. Respir. J.1019973843|
|207.||Kofford, M. W., L. B. Schwartz, N. M. Schechter, D. R.Yager, R. F. Diegelmann, and M. F. Graham. 1997. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272: 7127–7131.|
|208.||Welle M.Development, significance, and heterogeneity of mast cells with particular regard to the mast cell–specific proteases chymase and tryptase. J. Leukoc. Biol.611997233245|
|209.||Johnson P. R., Armour C. L., Carey D., Black J. L.Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am. J. Physiol.2691995L514L519|
|210.||Tyrell D. J., Kilfeather S., Page C. P.Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol. Sci.161995198204|
|211.||Green W. F., Konnaris K., Woolcock A. J.Effect of salbutamol, fenoterol, and sodium cromoglycate on the release of heparin from sensitized human lung fragments challenged with Dermatophagoides pteronyssinus allergen. Am. J. Respir. Cell Mol. Biol.81993518521|
|212.||Ahmed T., Garrigo J., Danta I.Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin [see comments]. N. Engl. J. Med.32919939095|
|213.||Bowler S. D., Smith S. M., Lavercombe P. S.Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis.1471993160163|
|214.||Diamant Z., Timmers M. C., van der Veen H., Page C. P., van der Meer F. J., Sterk P. J.Effect of inhaled heparin on allergen- induced early and late asthmatic responses in patients with atopic asthma. Am. J. Respir. Crit. Care Med.153199617901795|
|215.||Polosa R., Magri S., Vancheri C., Armato F., Santonocito G., Mistretta A., Crimi N.Time course of changes in adenosine 5′-monophosphate airway responsiveness with inhaled heparin in allergic asthma. J. Allergy Clin. Immunol.991997338344|
|216.||Bradding P., Feather I. H., Howarth P. H., Mueller R., Roberts J. A., Britten K., Bews J. P., Hunt T. C., Okayama Y., Heusser C. H., Bullock G. R., Church M. K., Holgate S. T.Interleukin 4 is localized to and released by human mast cells. J. Exp. Med.176199213811386|
|217.||MacGlashan D., White J. M., Huang S. K., Ono S. J., Schroeder J. T., Lichtenstein L. M.Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J. Immunol.152199430063016|
|218.||Ochensberger B., Daepp G. C., Rihs S., Dahinden C. A.Human blood basophils produce interleukin-13 in response to IgE-receptor-dependent and -independent activation. Blood88199630283037|
|219.||Young L. S., Eliopoulos A. G., Gallagher N. J., Dawson C. W.CD40 and epithelial cells: across the great divide. Immunol. Today191998502506|
|220.||Kawanami O., Ferrans V. J., Fulmer J. D., Crystal R. G.Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab. Invest.401979717734|
|221.||Jordana M.Mast cells and fibrosis—who's on first? Am. J. Respir. Cell Mol. Biol.8199378|
|222.||Chanez P., Lacoste J. Y., Guillot B., Giron J., Barneon G., Enander I., Godard P., Michel F. B., Bousquet J.Mast cell's contribution to the fibrosing alveolitis of the scleroderma lung. Am. Rev. Respir. Dis.147199314971502|
|223.||Ruoss S. J., Hartmann T., Caughey G. H.Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest.881991493499|
|224.||Nagata Y., Matsumura F., Motoyoshi H., Yamasaki H., Fukuda K., Tanaka S.Secretion of hyaluronic acid from synovial fibroblasts is enhanced by histamine: a newly observed metabolic effect of histamine. J. Lab. Clin. Med.1201992707712|
|225.||Thompson H. L., Burbelo P. D., Gabriel G., Yamada Y., Metcalfe D. D.Murine mast cells synthesize basement membrane components: a potential role in early fibrosis. J. Clin. Invest.871991619623|
|226.||Meininger C. J., Zetter B. R.Mast cells and angiogenesis. Semin. Cancer Biol.319927379|
|227.||Gruber B. L., Kew R. R., Jelaska A., Marchese M. J., Garlick J., Ren S., Schwartz L. B., Korn J. H.Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol.158199723102317|
|228.||Cairns J. A., Walls A. F.Mast cell tryptase is a mitogen for epithelial cells: stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J. Immunol.1561996275283|
|229.||Poulter L. W., Power C., Burke C.The relationship between bronchial immunopathology and hyperresponsiveness in asthma. Eur. Respir. J.31990792799|
|230.||Bentley A. M., Menz G., Storz C., Robinson D. S., Bradley B., Jeffery P. K., Durham S. R., Kay A. B.Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma: relationship to symptoms and bronchial responsiveness. Am. Rev. Respir. Dis.1461992500506|
|231.||Joseph M., Tonnel A. B., Torpier G., Capron A., Arnoux B., Benveniste J.Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J. Clin. Invest.711983221230|
|232.||Fuller R. W., O'Malley G., Baker A. J., MacDermot J.Human alveolar macrophage activation: inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition. Pulm. Pharmacol.11988101106|
|233.||Borish L., Mascali J. J., Dishuck J., Beam W. R., Martin R. J., Rosenwasser L. J.Detection of alveolar macrophage-derived IL-1 beta in asthma: inhibition with corticosteroids. J. Immunol.149199230783082|
|234.||Chanez P., Vignola A. M., Paul-Eugene N., Dugas B., Godard P., Michel F. B., Bousquet J.Modulation by interleukin-4 of cytokine release from mononuclear phagocytes in asthma. J. Allergy Clin. Immunol.9419949971005|
|235.||Chanez P., Vignola A. M., Albat B., Springall D. R., Polak J. M., Godard P., Bousquet J.Involvement of endothelin in mononuclear phagocyte inflammation in asthma. J. Allergy Clin. Immunol.981996412420|
|236.||Cluzel M., Damon M., Chanez P., Bousquet J., Crastes de Paulet A., Michel F. B., Godard P.Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. J. Allergy Clin. Immunol.801987195201|
|237.||Kelly C., Ward C., Stenton C. S., Bird G., Hendrick D. J., Walters E. H.Number and activity of inflammatory cells in bronchoalveolar lavage fluid in asthma and their relation to airway responsiveness. Thorax431988684692|
|238.||Metzger W. J., Zavala D., Richerson H. B., Moseley P., Iwamota P., Monick M., Sjoerdsma K., Hunninghake G. W.Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs: description of the model and local airway inflammation. Am. Rev. Respir. Dis.1351987433440|
|239.||Gosset P., Tsicopoulos A., Wallaert B., Vannimenus C., Joseph M., Tonnel A. B., Capron A.Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J. Allergy Clin. Immunol.881991561571|
|240.||Damon M., Chavis C., Daures J. P., Crastes de Paulet A., Michel F. B., Godard P.Increased generation of the arachidonic metabolites LTB4 and 5-HETE by human alveolar macrophages in patients with asthma: effect in vitro of nedocromil sodium. Eur. Respir. J.21989202209|
|241.||Arnoux B., Jouvin-Marche E., Arnoux A., Chrétien J., Benveniste J.Release of PAF-acether from human monocytes. Agents Action121982713716|
|242.||Sperber K., Chanez P., Bousquet J., Goswami S., Marom Z.Detection of a novel macrophage-derived mucus secretagogue (MMS-68) in bronchoalveolar lavage fluid of patients with asthma. J. Allergy Clin. Immunol.951995868876|
|243.||Aubas P., Cosso B., Godard P., Michel F. B., Clot J.Decreased suppressor cell activity of alveolar macrophages in bronchial asthma. Am. Rev. Respir. Dis.1301984875878|
|244.||Poulter L. W., Janossy G., Power C., Sreenan S., Burke C.Immunological/physiological relationships in asthma: potential regulation by lung macrophages. Immunol. Today151994258261|
|245.||Kovacs E., DiPietro L.Fibrogenic cytokines and connective tissue production. FASEB J.81994854861|
|246.||Chapman H. A., Allen C. L., Stone O. L.Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am. Rev. Respir. Dis.1331986437443|
|247.||Lyberg T., Nakstad B., Hetland O., Boye N. P.Procoagulant (thromboplastin) activity in human bronchoalveolar lavage fluids is derived from alveolar macrophages. Eur. Respir. J.319906167|
|248.||Piguet P. F., Ribaux C., Karpuz V., Grau G. E., Kapanci Y.Expression and localization of tumor necrosis factor-alpha, and its mRNA in idiopathic pulmonary fibrosis. Am. J. Pathol.1431993651655|
|249.||Standiford T. J., Rolfe M. W., Kunkel S. L., Lynch J. D., Burdick M. D., Gilbert A. R., Orringer M. B., Whyte R. I., Strieter R. M.Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J. Immunol.151199328522863|
|250.||Antoniades H. N., Bravo M. A., Avila R. E., Galanopoulos T., Neville-Golden J., Maxwell M., Selman M.Platelet-derived growth factor in idiopathic pulmonary fibrosis. J. Clin. Invest.86199010551064|
|251.||Marinelli W. A., Polunovsky V. A., Harmon K. R., Bitterman P. B.Role of platelet-derived growth factor in pulmonary fibrosis [comment]. Am. J. Respir. Cell Mol. Biol.51991503504|
|252.||Vignaud J. M., Allam M., Martinet N., Pech M., Plenat F., Martinet Y.Presence of platelet-derived growth factor in normal and fibrotic lung is specifically associated with interstitial macrophages, while both interstitial macrophages and alveolar epithelial cells express the c-sis proto-oncogene [see comments]. Am. J. Respir. Cell Mol. Biol.51991531538|
|253.||Shaw R. J., Benedict S. H., Clark R. A., King T.Pathogenesis of pulmonary fibrosis in interstitial lung disease: alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. Am. Rev. Respir. Dis.1431991167173|
|254.||Vignola A. M., Chanez P., Chiappara G., Merendino A., Zinnanti E., Bousquet J., Bellia V., Bonsignore G.Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases. Clin. Exp. Immunol1061996114119|
|255.||Taylor I. K., Sorooshian M., Wangoo A., Haynes A. R., Kotecha S., Mitchell D. M., Shaw R. J.Platelet-derived growth factor-beta mRNA in human alveolar macrophages in vivo in asthma. Eur. Respir. J.7199419661972|
|256.||Sunderkötter C., Steinbrink K., Goebeler M., Bhardawaj R., Sorg C.Macrophages and angiogenesis. J. Leukocyte Biol.551994410422|
|257.||Shaw R. J.The role of lung macrophages at the interface between chronic inflammation and fibrosis. Respir. Med.851991267273|
|258.||Fahy J. V., Liu J., Wong H., Boushey H. A.Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev. Respir. Dis.147199311261131|
|259.||Sur S., Crotty T. B., Kephart G. M., Hyma B. A., Colby T. V., Reed C. E., Hunt L. W., Gleich G. J.Sudden-onset fatal asthma: a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis.1481993713719|
|260.||Carroll N., Carello S., Cooke C., James A.Airway structure and inflammatory cells in fatal attacks of asthma. Eur. Respir. J.91996709715|
|261.||Martin R. J., Cicutto L. C., Smith H. R., Ballard R. D., Szefler S. J.Airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis.1431991351357|
|262.||Foresi A., Bertorelli G., Pesci A., Chetta A., Olivieri D.Inflammatory markers in bronchoalveolar lavage and in bronchial biopsy in asthma during remission. Chest981990528535|
|263.||Tanizaki Y., Kitani H., Mifune T., Mitsunobu F., Kajimoto K., Sugimoto K.Effects of glucocorticoids on humoral and cellular immunity and on airway inflammation in patients with steroid- dependent intractable asthma. J. Asthma301993485492|
|264.||Hance A. J.Pulmonary immune cells in health and disease: dendritic cells and Langerhans' cells. Eur. Respir. J.6199312131220|
|265.||Moser M., De Smedt T., Sornasse T., Tielemans F., Chentoufi A. A., Muraille E., Van Mechelen M., Urbain J., Leo O.Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur. J. Immunol.25199528182824|
|266.||Semper A. E., Hartley J. A., Tunon-de-Lara J. M., Bradding P., Redington A. E., Church M. K., Holgate S. T.Expression of the high affinity receptor for immunoglobulin E (IgE) by dendritic cells in normals and asthmatics. Adv. Exp. Med. Biol.3781995135138|
|267.||Tunon-De-Lara J. M., Redington A. E., Bradding P., Church M. K., Hartley J. A., Semper A. E., Holgate S. T.Dendritic cells in normal and asthmatic airways:expression of the alpha subunit of the high affinity immunoglobulin E receptor (Fc epsilon RI-alpha). Clin. Exp. Allergy261996648655|
|268.||Moller G. M., Overbeek S. E., Van Helden-Meeuwsen C. G., Van Haarst J. M., Prens E. P., Mulder P. G., Postma D. S., Hoogsteden H. C.Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Clin. Exp. Allergy261996517424|
|269.||Lambrecht B., Pauwels R., Bullock G.The dendritic cell: its potent role in the respiratory immune response. Cell Biol. Int.201996111120|
|270.||Sheppard M. N., Harrison N. K.New perspectives on basic mechanisms in lung disease: 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis. Thorax47199210641074|
|271.||Doucet C., Brouty-Boye D., Pottin-Clemenceau C., Canonica G. W., Jasmin C., Azzarone B.Interleukin (IL) 4 and IL-13 act on human lung fibroblasts: implication in asthma. J. Clin. Invest.101199821292139|
|272.||Gizycki M., Adelroth E., Rodgers A., O'Byrne P., Jeffery P.Myofibroblast involvement in allergen-induced late response in mild asthma. Am. J. Respir. Cell Mol. Biol.161997664673|
|273.||Zhang S., Mohammed Q., Burbidge A., Morland C. M., Roche W. R.Cell cultures from bronchial subepithelial myofibroblasts enhance eosinophil survival in vitro. Eur. Respir. J.9199618391846|
|274.||Zhang S., Howarth P. H., Roche W. R.Cytokine production by cell cultures from bronchial subepithelial myofibroblasts. J. Pathol.180199695101|
|275.||Leslie K. O., Mitchell J., Low R.Lung myofibroblasts. Cell. Motil. Cytoskeleton2219929298|
|276.||Kuhn C., McDonald J. A.The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol.138199112571265|
|277.||Brewster C. E., Howarth P. H., Djukanovic R., Wilson J., Holgate S. T., Roche W. R.Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol.31990507511|
|278.||Gabbrielli S., Di Lollo S., Stanflin N., Romagnoli P.Myofibroblast and elastic and collagen fiber hyperplasia in the bronchial mucosa: a possible basis for the progressive irreversibility of airway obstruction in chronic asthma. Pathologica861994157160|
|279.||Taytard A., Guenard H., Vuillemin L., Bouvot J. L., Vergeret J., Ducassou D., Piquet Y., Freour P.Platelet kinetics in stable atopic asthmatic patients. Am. Rev. Respir. Dis.1341986983985|
|280.||Page C.The role of platelets in allergic disease [editorial; comment]. Clin. Exp. Allergy201990339340|
|281.||Joseph M., Capron A., Tsicopoulos A., Ameisen J. C., Martinot J. B., Tonnel A. B.Platelet activation by IgE and aspirin. Agents Actions Suppl.211987169177|
|282.||Morrison J. F., Pearson S. B., Dean H. G., Craig I. R., Bramley P. N.Platelet activation in nocturnal asthma. Thorax461991197200|
|283.||Solway J., Leff A. R.Sensory neuropeptides and airway function. J. Appl. Physiol.71199120772087|
|284.||Barnes P. J.Neurogenic inflammation and asthma. J. Asthma291992165180|
|285.||Joos G. F., Germonpre P. R., Kips J. C., Peleman R. A., Pauwels R. A.Sensory neuropeptides and the human lower airways: present state and future directions. Eur. Respir. J.7199411611171|
|286.||Bertrand C., Geppetti P.Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Trends Pharmacol. Sci.171996255259|
|287.||Barnes P. J.Neuroeffector mechanisms: the interface between inflammation and neuronal responses. J. Allergy Clin. Immunol.981996S81S83|
|288.||Virchow J. C., Julius P., Lommatzsch M., Luttmann W., Renz H., Braun A.Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation. Am. J. Respir. Crit. Care Med.158199820022005|
|289.||Arm J. P., Lee T. H.Sulphidopeptide leukotrienes in asthma [editorial]. Clin. Sci. Colch.841993501510|
|290.||Dahlen B., Dahlen S. E.Leukotrienes as mediators of airway obstruction and inflammation in asthma. Clin. Exp. Allergy219955054|
|291.||O'Byrne P. M.Leukotrienes in the pathogenesis of asthma. Chest111199727S34S|
|292.||Shaw R. J., Cromwell O., Kay A. B.Preferential generation of leukotriene C4 by human eosinophils. Clin. Exp. Immunol561984716722|
|293.||Dahlen S. E., Hedqvist P., Hammarstrom S., Samuelsson B.Leukotrienes are potent constrictors of human bronchi. Nature2881980484486|
|294.||Griffin M., Weiss J. W., Leitch A. G., McFadden E., Corey E. J., Austen K. F., Drazen J. M.Effects of leukotriene D on the airways in asthma. N. Engl. J. Med.3081983436439|
|295.||Marom Z., Shelhamer J. H., Bach M. K., Morton D. R., Kaliner M.Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am. Rev. Respir. Dis.1261982449451|
|296.||Adelroth E., Morris M. M., Hargreave F. E., O'Byrne P. M.Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N. Engl. J. Med.3151986480484|
|297.||O'Hickey S. P., Hawksworth R. J., Fong C. Y., Arm J. P., Spur B.W., Lee T. H.Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am. Rev. Respir. Dis.144199110531057|
|298.||Laitinen L. A., Laitinen A., Haahtela T., Vilkka V., Spur B. W., Lee T. H.Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet3411993989990|
|299.||Diamant Z., Hiltermann J. T., van-Rensen E. L., Callenbach P. M., Veselic-Charvat M., van-der-Veen H., Sont J. K., Sterk P. J.The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am. J. Respir. Crit. Care Med.155199712471253|
|300.||Datta Y. H., Romano M., Jacobson B. C., Golan D. E., Serhan C. N., Ewenstein B. M.Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation92199533043311|
|301.||Henderson W., Lewis D. B., Albert R. K., Zhang Y., Lamm W. J., Chiang G. K., Jones F., Eriksen P., Tien Y. T., Jonas M., Chi E. Y.The importance of leukotrienes in airway inflammation in a mouse model of asthma. J. Exp. Med.184199614831494|
|302.||Cohen P., Noveral J. P., Bhala A., Nunn S. E., Herrick D. J., Grunstein M. M.Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am. J. Physiol.2691995L151L157|
|303.||Panettieri R. A., Tan E. M., Ciocca V., Luttmann M. A., Leonard T. B., Hay D. W.Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am. J. Respir. Cell Mol. Biol.191998453461|
|304.||Leikauf G. D., Claesson H. E., Doupnik C. A., Hybbinette S., Grafstrom R. C.Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am. J. Physiol.2591990L255L261|
|305.||Medina L., Perez-Ramos J., Ramirez R., Selman M., Pardo A.Leukotriene C4 upregulates collagenase expression and synthesis in human lung fibroblasts. Biochim. Biophys. Acta12241994168174|
|306.||Israel E., Fischer A. R., Rosenberg M. A., Lilly C. M., Callery J. C., Shapiro J., Cohn J., Rubin P., Drazen J. M.The pivotal role of 5-lipoxygenase products in the reaction of aspirin–sensitive asthmatics to aspirin. Am. Rev. Respir. Dis.148199314471451|
|307.||Sladek K., Dworski R., Soja J., Sheller J. R., Nizankowska E., Oates J. A., Szczeklik A.Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am. J. Respir. Crit. Care Med.1491994940946|
|308.||Cowburn A. S., Sladek K., Soja J., Adamek L., Nizankowska E., Szczeklik A., Lam B. K., Penrose J. F., Austen F. K., Holgate S. T., Sampson A. P.Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest.1011998834846|
|309.||In K. H., Asano K., Beier D., Grobholz J., Finn P. W., Silverman E. K., Silverman E. S., Collins T., Fischer A. R., Keith T. P., Serino K., Kim S. W., De Sanctis G. T., Yandava C., Pillari A., Rubin P., Kemp J., Israel E., Busse W., Ledford D., Murray J. J., Segal A., Tinkleman D., Drazen J. M.Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest.99199711301137|
|310.||Nomura A., Uchida Y., Kameyana M., Saotome M., Oki K., Hasegawa S.Endothelin and bronchial asthma [letter]. Lancet21989747748|
|311.||Redington A. E., Springall D. R., Ghatei M. A., Lau L. C., Bloom S. R., Holgate S. T., Polak J. M., Howarth P. H.Endothelin in bronchoalveolar lavage fluid and its relation to airflow obstruction in asthma. Am. J. Respir. Crit. Care Med.151199510341039|
|312.||Kraft M., Beam W. R., Wenzel S. E., Zamora M. R., O'Brien R. F., Martin R. J.Blood and bronchoalveolar lavage endothelin-1 levels in nocturnal asthma. Am. J. Respir. Crit. Care Med.1491994946952|
|313.||Black P. N., Ghatei M. A., Takahashi K., Bretherton-Watt D., Krausz T., Dollery C. T., Bloom S. R.Formation of endothelin by cultured airway epithelial cells. FEBS Lett.2551989129132|
|314.||Luscher T. F.Endothelin: systemic arterial and pulmonary effects of a new peptide with potent biologic properties. Am. Rev. Respir. Dis.1461992S56S60|
|315.||Nagase T., Fukuchi Y., Jo C., Teramoto S., Uejima Y., Ishida K., Shimizu T., Orimo H.Endothelin-1 stimulates arachidonate 15-lipoxygenase activity and oxygen radical formation in the rat distal lung. Biochem. Biophys. Res. Commun.1681990485489|
|316.||Haller H., Schaberg T., Lindschau C., Lode H., Distler A.Endothelin increases [Ca2+]i, protein phosphorylation, and O2-. production in human alveolar macrophages. Am. J. Physiol.2611991L478L484|
|317.||Kharitonov S. A., Yates D., Robbins R. A., Logan-Sinclair R., Shinebourne E. A., Barnes P. J.Increased nitric oxide in exhaled air of asthmatic patients. Lancet3431994133135|
|318.||Kacmarek R. M., Ripple R., Cockrill B. A., Bloch K. J., Zapol W. M., Johnson D. C.Inhaled nitric oxide: a bronchodilator in mild asthmatics with methacholine-induced bronchospasm. Am. J. Respir. Crit. Care Med.1531996128135|
|319.||Barnes P. J.Nitric oxide and airway disease. Ann. Med.271995389393|
|320.||Boulet L. P., Milot J., Boutet M., St-Georges F., Laviolette M.Airway inflammation in nonasthmatic subjects with chronic cough. Am. J. Respir. Crit. Care Med.1491994482489|
|321.||Fabbri L. M.Airway inflammation in occupational asthma. Am. J. Respir. Crit. Care Med.1501994S80S82|
|322.||Nasser S. M., Pfister R., Christie P. E., Sousa A. R., Barker J., Schmitz-Schumann M., Lee T. H.Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am. J. Respir. Crit. Care Med.15319969096|
|323.||Walker C., Virchow J., Bruijnzeel P. L., Blaser K.T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J. Immunol.146199118291835|
|324.||Humbert M.Airways inflammation in asthma, and chronic bronchitis [editorial; comment]. Clin. Exp. Allergy261996735737|
|325.||Ying, S., M. Humbert, J. Barkans, C. J. Corrigan, R. Pfister, G. Menz, M. Larche, D. S. Robinson, S. R.Durham, and A. B. Kay. 1997. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J. Immunol. 158:3539–3544.|
|326.||Djukanovic R., Feather I., Gratziou C., Walls A., Peroni D., Bradding P., Judd M., Howarth P. H., Holgate S. T.Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax511996575581|
|327.||Boulet L. P., Boutet M., Laviolette M., Dugas M., Milot J., Leblanc C., Paquette L., Cote J., Cartier A., Malo J. L.Airway inflammation after removal from the causal agent in occupational asthma due to high and low molecular weight agents [see comments]. Eur. Respir. J.7199415671575|
|328.||Muller-Suur C., Larsson K., Malmberg P., Larsson P. H.Increased number of activated lymphocytes in human lung following swine dust inhalation. Eur. Respir. J.101997376380|
|329.||Devalia J. L., Rusznak C., Herdman M. J., Trigg C. J., Tarraf H., Davies R. J.Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation. Lancet344199416681671|
|330.||Krishna M. T., Springall D. R., Frew A. J., Polak J. M., Holgate S. T.Mediators of inflammation in response to air pollution: a focus on ozone and nitrogen dioxide. J. R. Coll. Physicians Lond.3019966166|
|331.||Kinney P. L., Nilsen D. M., Lippmann M., Brescia M., Gordon T., McGovern T., El-Fawal H., Devlin R. B., Rom W. N.Biomarkers of lung inflammation in recreational joggers exposed to ozone. Am. J. Respir. Crit. Care Med.154199614301435|
|332.||Fraenkel D. J., Bardin P. G., Sanderson G., Lampe F., Johnston S. L., Holgate S. T.Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am. J. Respir. Crit. Care Med.1511995879886|
|333.||Calhoun W. J., Dick E. C., Schwartz L. B., Busse W. W.A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J. Clin. Invest.94199422002208|
|334.||Busse W. W.The role of respiratory infections in airway hyperresponsiveness and asthma. Am. J. Respir. Crit. Care Med.1501994S77S79|
|335.||Laitinen L. A., Laitinen A., Haahtela T.Airway mucosal inflammation even in patients with newly diagnosed asthma. Am. Rev. Respir. Dis.1471993697704|
|336.||Vignola A. M., Chanez P., Campbell A. M., Souques F., Lebel B., Enander I., Bousquet J.Airway inflammation in mild intermittent and in persistent asthma. Am. J. Respir. Crit. Care Med.1571998403409|
|337.||Demoly P., Basset-Seguin N., Chanez P., Campbell A. M., Gauthier-Rouviere C., Godard P., Michel F. B., Bousquet J.c-fos proto-oncogene expression in bronchial biopsies of asthmatics. Am. J. Respir. Cell Mol. Biol.71992128133|
|338.||Roisman G. L., Peiffer C., Lacronique J. G., Le-Cae A., Dusser D. J.Perception of bronchial obstruction in asthmatic patients: relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment. J. Clin. Invest.9619951221|
|339.||Ward C., Kelly C. A., Stenton S. C., Duddridge M., Hendrick D. J., Walters E. H.The relative contribution of bronchoalveolar macrophages and neutrophils to lucigenin- and luminol-amplified chemiluminescence [see comments]. Eur. Respir. J.3199010081014|
|340.||Kraft M., Djukanovic R., Torvik J., Cunningham L., Henson J., Wilson S., Holgate S. T., Hyde D., Martin R.Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest1071995162S|
|341.||Oosterhoff Y., Kauffman H. F., Rutgers B., Zijlstra F. J., Koeter G. H., Postma D. S.Inflammatory cell number and mediators in bronchoalveolar lavage fluid and peripheral blood in subjects with asthma with increased nocturnal airways narrowing. J. Allergy Clin. Immunol.961995219229|
|342.||Jarjour N. N., Busse W. W., Calhoun W. J.Enhanced production of oxygen radicals in nocturnal asthma. Am. Rev. Respir. Dis.1461992905911|
|343.||Oosterhoff Y., Hoogsteden H. C., Rutgers B., Kauffman H. F., Postma D. S.Lymphocyte and macrophage activation in bronchoalveolar lavage fluid in nocturnal asthma. Am. J. Respir. Crit. Care Med.15119957581|
|344.||Barnes P., FitzGerald G., Brown M., Dollery C.Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N. Engl. J. Med.3031980263267|
|345.||Szefler S. J., Ando R., Cicutto L. C., Surs W., Hill M. R., Martin R. J.Plasma histamine, epinephrine, cortisol, and leukocyte beta-adrenergic receptors in nocturnal asthma. Clin. Pharmacol. Ther.4919915968|
|346.||Fitzpatrick M. F., Mackay T., Walters C., Tai P. C., Church M. K., Holgate S. T., Douglas N. J.Circulating histamine and eosinophil cationic protein levels in nocturnal asthma. Clin. Sci.831992227232|
|347.||Mackay T. W., Wallace W. A., Howie S. E., Brown P. H., Greening A. P., Church M. K., Douglas N. J.Role of inflammation in nocturnal asthma. Thorax491994257262|
|348.||Turki J., Pak J., Green S. A., Martin R. J., Liggett S. B.Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. J. Clin. Invest.95199516351641|
|349.||Gibson P. G., Wong B. J., Hepperle M. J., Kline P. A., Girgis-Gabardo A., Guyatt G., Dolovich J., Denburg J. A., Ramsdale E. H., Hargreave F. E.A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin. Exp. Allergy221992525532|
|350.||Fabbri L., Burge P. S., Croonenborgh L., Warlies F., Weeke B., Ciaccia A., Parker C.Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group [see comments]. Thorax481993817823|
|351.||Chervinsky P., van As A., Bronsky E. A., Dockhorn R., Noonan M., LaForce C., Pleskow W.Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma: The Fluticasone Propionate Asthma Study Group. J. Allergy Clin. Immunol.941994676683|
|352.||Pauwels R. A., Lofdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A.Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [see comments]. N. Engl. J. Med.337199714051411|
|353.||Boushey H. A.Bronchial hyperreactivity to sulfur dioxide: physiologic and political implications. J. Allergy Clin. Immunol.691982335338|
|354.||Sterk P. J.The place of airway hyperresponsiveness in the asthma phenotype. Clin. Exp. Allergy21995811|
|355.||Postma D. S., Bleecker E. R., Amelung P. J., Holroyd K. J., Xu J., Panhuysen C. I., Meyers D. A., Levitt R. C.Genetic susceptibility to asthma–bronchial hyperresponsiveness coinherited with a major gene for atopy. N. Engl. J. Med.3331995894900|
|356.||Busse W. W., Coffman R. L., Gelfand E. W., Kay A. B., Rosenwasser L. J.Mechanisms of persistent airway inflammation in asthma: a role for T cells, and T-cell products. Am. J. Respir. Crit. Care Med.1521995388393|
|357.||Thomas P. S., Yates D. H., Barnes P. J.Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am. J. Respir. Crit. Care Med.15219957680|
|358.||Sparrow M. P., Omari T. I., Mitchell H. W.The epithelial barrier and airway responsiveness. Can. J. Physiol. Pharmacol.731995180190|
|359.||Schoonbrood D. F., Lutter R., Habets F. J., Roos C. M., Jansen H. M., Out T. A.Analysis of plasma-protein leakage and local secretion in sputum from patients with asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.150199415191527|
|360.||Goldie R. G., Pedersen K. E.Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Clin. Exp. Pharmacol. Physiol.221995387396|
|361.||Virchow J., Holscher U., Virchow C.Sputum ECP levels correlate with parameters of airflow obstruction. Am. Rev. Respir. Dis.1461992604606|
|362.||Chetta A., Foresi A., Del Donno M., Consigli G. F., Bertorelli G., Pesci A., Barbee R. A., Olivieri D.Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am. J. Respir. Crit. Care Med.1531996910917|
|363.||Crimi E., Spanevello A., Neri M., Ind P. W., Rossi G. A., Brusasco V.Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma [see comments]. Am. J. Respir. Crit. Care Med.157199849|
|364.||McFadden E., Gilbert I. A.Asthma. N. Engl. J. Med.327199219281937|
|365.||International Asthma Management ProjectInternational Consensus Report on Diagnosis and Management of Asthma. Allergy471992161|
|366.||Barnes P. J.Inhaled glucocorticoids for asthma. N. Engl. J. Med.3321995868875|
|367.||Noonan M., Chervinsky P., Busse W. W., Weisberg S. C., Pinnas J., de-Boisblanc B. P., Boltansky H., Pearlman D., Repsher L., Kellerman D.Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am. J. Respir. Crit. Care Med.152199514671473|
|368.||Barnes P. J., Karin M.Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med.336199710661071|
|369.||Schwiebert L. A., Beck L. A., Stellato C., Bickel C. A., Bochner B. S., Schleimer R. P.Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J. Allergy Clin. Immunol.971996143152|
|370.||Adelroth E., Rosenhall L., Johansson S. A., Linden M., Venge P.Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: the effects of antiasthmatic treatment with budesonide or terbutaline. Am. Rev. Respir. Dis.14219909199|
|371.||Burke C., Power C. K., Norris A., Condez A., Schmekel B., Poulter L. W.Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma. Eur. Respir. J.519927379|
|372.||Djukanovic R., Wilson J. W., Britten K. M., Wilson S. J., Walls A. F., Roche W. R., Howarth P. H., Holgate S. T.Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis.1451992669674|
|373.||Laitinen L. A., Laitinen A., Haahtela T.A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol.9019923242|
|374.||Duddridge M., Ward C., Hendrick D. J., Walters E. H.Changes in bronchoalveolar lavage inflammatory cells in asthmatic patients treated with high dose inhaled beclomethasone dipropionate. Eur. Respir. J.61993489497|
|375.||Corrigan C. J., Haczku A., Gemou-Engesaeth V., Doi S., Kikuchi Y., Takatsu K., Durham S. R., Kay A. B.CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5: effect of glucocorticoid therapy. Am. Rev. Respir. Dis.1471993540547|
|376.||Wilson J. W., Djukanovic R., Howarth P. H., Holgate S. T.Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. Am. J. Respir. Crit. Care Med.14919948690|
|377.||Hoshino M., Nakamura Y.Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics. Eur. Respir. J.91996696702|
|378.||Trigg C. J., Manolitsas N. D., Wang J., Calderon M. A., McAulay A., Jordan S. E., Herdman M. J., Jhalli N., Duddle J. M., Hamilton S. A.Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am. J. Respir. Crit. Care Med.15019941722|
|379.||Sont J., van Krieken J., Evertse C., Hooijer R., Willems L., Sterk P.Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax511996496502|
|380.||Kharitonov S. A., Yates D. H., Barnes P. J.Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am. J. Respir. Crit. Care Med.1531996454457|
|381.||Gerber F., Fournier M., Pariente R.Effets des gluco-corticostéroids dans l'asthme à dyspnée continue: étude histologique et immuno-histochimique de la muqueuse bronchique. Rev. Mal. Respir.21985313317|
|382.||Robinson D., Hamid Q., Ying S., Bentley A., Assoufi B., Durham S., Kay A. B.Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression. Am. Rev. Respir. Dis.1481993401406|
|383.||Robinson D. S., Assoufi B., Durham S. R., Kay A. B.Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma: effect of prednisolone treatment. Clin. Exp. Allergy25199511181127|
|384.||Djukanovic R., Homeyard S., Gratziou C., Madden J., Walls A., Montefort S., Peroni D., Polosa R., Holgate S., Howarth P.The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am. J. Respir. Crit. Care Med.1551997826832|
|385.||Dworski R., Fitzgerald G. A., Oates J. A., Sheller J. R.Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med.1491994953959|
|386.||Bentley A. M., Hamid Q., Robinson D. S., Schotman E., Meng Q., Assoufi B., Kay A. B., Durham S. R.Prednisolone treatment in asthma: reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am. J. Respir. Crit. Care Med.1531996551556|
|387.||Corrigan C., Haczku A., Gemou-Engesaeth V., Doi S., Kikuchi Y., Takatsu K., Durham S., Kay A.Peripheral blood T-lymphocyte activation in asthma is accompanied by elevated serum concentrations of IL-5: effect of glucocorticoid therapy. Am. Rev. Respir. Dis.1471993540547|
|388.||Naseer T., Minshall E. M., Leung D. Y., Laberge S., Ernst P., Martin R. J., Hamid Q.Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am. J. Respir. Crit. Care Med.1551997845851|
|389.||Doull I. J., Lampe F. C., Smith S., Schreiber J., Freezer N. J., Holgate S. T.Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. B.M.J.3151997858862|
|390.||Carmichael J., Paterson I. C., Diaz P., Crompton G. K., Kay A. B., Grant I. W.Corticosteroid resistance in chronic asthma. Br. Med. J. Clin. Res.282198114191422|
|391.||Woolcock A. J.Steroid resistant asthma: what is the clinical definition? Eur. Respir. J.61993743747|
|392.||Holgate S. T.Inhaled sodium cromoglycate. Respir. Med.901996387390|
|393.||Manolitsas N. D., Wang J., Devalia J. L., Trigg C. J., McAulay A. E., Davies R. J.Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am. J. Respir. Crit. Care Med.151199519251930|
|394.||Altraja A., Laitinen A., Meriste S., Marran S., Martson T., Sillastu H., Laitinen L. A.Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. J. Allergy Clin. Immunol.981996S6466|
|395.||Calhoun W. J., Jarjour N. N., Gleich G. J., Schwartz L. B., Busse W. W.Effect of nedocromil sodium pretreatment on the immediate and late responses of the airway to segmental antigen challenge. J. Allergy Clin. Immunol.981996S46S50|
|396.||Hoshino M., Nakamura Y.The effect of inhaled sodium cromoglycate on cellular infiltration into the bronchial mucosa and the expression of adhesion molecules in asthmatics. Eur. Respir. J.101997858865|
|397.||Sullivan P., Bekir S., Jaffar Z., Page C., Jeffery P., Costello J.Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet343199410061008|
|398.||Djukanovic R., Finnerty J. P., Lee C., Wilson S., Madden J., Holgate S. T.The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur. Respir. J.81995831883|
|399.||Kraft M., Torvik J. A., Trudeau J. B., Wenzel S. E., Martin R. J.Theophylline: potential antiinflammatory effects in nocturnal asthma. J. Allergy Clin. Immunol.97199612421246|
|400.||Finnerty J., Lee C., Wilson S., Madden J., Djukanovic R., Holgate S.Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. Eur. Respir. J.9199616721677|
|401.||Spector S. L., Smith L. J., Glass M.Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma: ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care Med.1501994618623|
|402.||Reiss T. F., Sorkness C. A., Stricker W., Botto A., Busse W. W., Kundu S., Zhang J.Effects of montelukast (MK-0476): a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax5219974548|
|403.||Israel E., Cohn J., Dube L., Drazen J. M.Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. Zileuton Clinical Trial Group. J.A.M.A.2751996931936|
|404.||McGill K. A., Busse W. W.Zileuton. Lancet3481996519524|
|405.||Kane G. C., Pollice M., Kim C. J., Cohn J., Dworski R. T., Murray J. J., Sheller J. R., Fish J. E., Peters S. P.A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J. Allergy Clin. Immunol.971996646654|
|406.||Tamaoki J., Kondo M., Sakai N., Nakata J., Takemura H., Nagai A., Takizawa T., Konno K.Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med.155199712351240|
|407.||Gardiner P. V., Ward C., Booth H., Allison A., Hendrick D. J., Walters E. H.Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am. J. Respir. Crit. Care Med.150199410061011|
|408.||Pizzichini M. M., Kidney J. C., Wong B. J., Morris M. M., Efthimiadis A., Dolovich J., Hargreave F. E.Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Eur. Respir. J.91996449455|
|409.||Lebel B., Arnoux B., Chanez P., Bougeard Y. H., Daures J. P., Bousquet J., Campbell A. M.Ex vivo pharmacologic modulation of basophil histamine release in asthmatic patients. Allergy511996394400|
|410.||Munoz N. M., Vita A. J., Neeley S. P., McAllister K., Spaethe S. M., White S. R., Leff A. R.Beta adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4. J. Pharmacol. Exp. Ther.2681994139143|
|411.||Greening A. P., Ind P. W., Northfield M., Shaw G.Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen & Hanburys Limited UK Study Group. Lancet3441994219224|
|412.||Woolcock A., Lundback B., Ringdal N., Jacques L. A.Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med.153199614811488|
|413.||van der Molen T., Postma D., Turner M., Meyboom de Jong B., Malo J., Chapman K., Grossman R., de-Graaff C., Riemersma R., Sears M.Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax521997535540|
|414.||Evans D. W., Salome C. M., King G. G., Rimmer S. J., Seale J. P., Woolcock A. J.Effect of regular inhaled salbutamol on airway responsiveness, and airway inflammation in rhinitic non-asthmatic subjects. Thorax521997136142|
|415.||Haahtela T.The importance of inflammation in early asthma. Respir. Med.891995461462|
|416.||Haahtela T., Jarvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Reinikainen K., Selroos O., Sovijarvi A., Stenius-Aarninala B., Svahn T., Tammivara R., Laitinen L.Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med.3251991388392|
|417.||Israel E., Drazen J. M.Treating mild asthma—when are inhaled steroids indicated? [editorial; comment]. N. Engl. J. Med.3311994737739|
|418.||Juniper E. F., Kline P. A., Vanzieleghem M. A., Hargreave F. E.Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J. Allergy Clin. Immunol.871991483489|
|419.||Waalkens H. J., Van Essen-Zandvliet E. E., Hughes M. D., Gerritsen J., Duiverman E. J., Knol K., Kerrebijn K. F.Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration: The Dutch Chronic Nonspecific Lung Disease Study Group. Am. Rev. Respir. Dis.148199312521257|
|420.||Rennard S. I.Repair mechanisms in asthma. J. Allergy Clin. Immunol.981996S278S286|
|421.||Bousquet J., Chanez P., Lacoste J. Y., White R., Vic P., Godard P., Michel F. B.Asthma: a disease remodeling the airways. Allergy471992311|
|422.||Boulet L., Belanger M., Carrier G.Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am. J. Respir. Crit. Care Med.1521995865871|
|423.||Awadh N., Müller N., Park C., Abboud R., FitzGerald J.Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution computed scanning. Thorax531988248254|
|424.||Kamm R. D., Drazen J. M.Airway hyperresponsiveness and airway wall thickening in asthma: a quantitative approach [editorial; comment]. Am. Rev. Respir. Dis.145199212491250|
|425.||Dunnill M., Massarella G., Anderson J.Comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax241969176179|
|426.||Hossain S., Heard B. E.Hyperplasia of bronchial muscle in chronic bronchitis. J. Pathol.1011970171184|
|427.||Heard B., S. H.Hyperplasia of bronchial muscle in asthma. J. Pathol.1101973319331|
|428.||Saetta M., Di Stefano A., Rosina C., Thiene G., Fabbri L. M.Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am. Rev. Respir. Dis.1431991138143|
|429.||Carroll N., Elliot J., Morton A., James A.The structure of large and small airways in nonfatal and fatal asthma. Am. Rev. Respir. Dis.1471993405410|
|430.||Hogg J. C.Pathology of asthma. J. Allergy Clin. Immunol.92199315|
|431.||Sobonya R. E.Quantitative structural alterations in long-standing allergic asthma. Am. Rev. Respir. Dis.1301984289292|
|432.||Ebina M., Yaegashi H., Takahashi T., Motomiya M., Tanemura M.Distribution of smooth muscles along the bronchial tree: a morphometric study of ordinary autopsy lungs. Am. Rev. Respir. Dis.141199013221326|
|433.||Ebina M., Takahashi T., Chiba T., Motomiya M.Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma: a 3-D morphometric study. Am. Rev. Respir. Dis.1481993720726|
|434.||Halayko A. J., Stephens N. L.Potential role for phenotypic modulation of bronchial smooth muscle cells in chronic asthma. Can. J. Physiol. Pharmacol.72199414481457|
|435.||Noveral J. P., Grunstein M. M.Role and mechanism of thromboxane–induced proliferation of cultured airway smooth muscle cells. Am. J. Physiol.2631992L555L561|
|436.||De S., Zelazny E. T., Souhrada J. F., Souhrada M.IL-1 beta and IL-6 induce hyperplasia and hypertrophy of cultured guinea pig airway smooth muscle cells. J. Appl. Physiol.78199515551563|
|437.||Noveral J. P., Rosenberg S. M., Anbar R. A., Pawlowski N. A., Grunstein M. M.Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells. Am. J. Physiol.2631992L317L324|
|438.||Stewart A. G., Grigoriadis G., Harris T.Mitogenic actions of endothelin-1 and epidermal growth factor in cultured airway smooth muscle. Clin. Exp. Pharmacol Physiol211994277285|
|439.||Shiels I. A., Bowler S. D., Taylor S. M.Airway smooth muscle proliferation in asthma: the potential of vascular leakage to contribute to pathogenesis. Med. Hypotheses.4519953740|
|440.||John M., Hirst S. J., Jose P. J., Robichaud A., Berkman N., Witt C., Twort C. H., Barnes P. J., Chung K. F.Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. J. Immunol.158199718411847|
|441.||Hirst S. J.Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. Eur. Respir. J.91996808820|
|442.||Benson M.Bronchial hyperreactivity. Br. J. Dis. Chest691975227239|
|443.||Freedman B.The functional geometry of the bronchi. Bull. Physiopath. Respir.81972545551|
|444.||Wiggs B. R., Moreno R., Hogg J. C., Hilliam C., Pare P. D.A model of the mechanics of airway narrowing. J. Appl. Physiol.691990849860|
|445.||James A. L., Pare P. D., Hogg J. C.The mechanics of airway narrowing in asthma. Am. Rev. Respir. Dis.1391989242246|
|446.||Wiggs B. R., Bosken C., Pare P. D., James A., Hogg J. C.A model of airway narrowing in asthma and in chronic obstructive pulmonary disease [see comments]. Am. Rev. Respir. Dis.145199212511258|
|447.||Moreno R. H., Hogg J. C., Pare P. D.Mechanics of airway narrowing. Am. Rev. Respir. Dis.133198611711180|
|448.||Holloway, L., R. Beasley, and W. Roche. 1995. The pathology of bronchial asthma. In W. W. Busse and S. L. Holgate, editors. Asthma and Rhinitis. Blackwell Scientific Publications, Oxford. 109–118.|
|449.||Dunnill M.The pathology of asthma with special references of changes in the bronchial mucosa. J. Clin. Pathol.1319602733|
|450.||Cluroe A., Holloway L., Thomson K., Purdie G., Beasley R.Bronchial gland duct ectasia in fatal bronchial asthma: association with interstitial emphysema. J. Clin. Pathol.42198910261031|
|451.||Cluroe A. D., Beasley R., Lorimer S., Holloway L.The relationship between pulmonary interstitial emphysema and clinical features in fatal asthma. J. Asthma3119946569|
|452.||Paganin F., Trussard V., Seneterre E., Chanez P., Giron J., Godard P., Senac J. P., Michel F. B., Bousquet J.Chest radiography and high resolution computed tomography of the lungs in asthma. Am. Rev. Respir. Dis.146199210841087|
|453.||Aikawa T., Shimura S., Sasaki H., Ebina M., Takishima T.Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest1011992916921|
|454.||Shimura S., Andoh Y., Haraguchi M., Shirato K.Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur. Respir. J.9199613951401|
|455.||Houston J., de Nevasquez S., Trounce J.A clinical and pathological study of fatal cases of status asthmaticus. Thorax81953207213|
|456.||Reid L. M.The presence or absence of bronchial mucus in fatal asthma. J. Allergy Clin. Immunol.801987415416|
|457.||Cardell B., Pearson R.Deaths in asthmatics. Thorax141959341352|
|458.||Messer J., Peters G., Bennett W.Causes of deaths and pathological findings in 304 cases of bronchial asthma. Br. J. Dis. Chest381960616624|
|459.||Sheehan J. K., Richardson P. S., Fung D. C., Howard M., Thornton D. J.Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am. J. Respir. Cell Mol. Biol.131995748756|
|460.||Pavia D., Bateman J. R., Sheahan N. F., Agnew J. E., Clarke S. W.Tracheobronchial mucociliary clearance in asthma: impairment during remission. Thorax401985171175|
|461.||Cutz E., Levison H., Cooper D. M.Ultrastructure of airways in children with asthma. Histopathology21978407421|
|462.||Roche W. R., Beasley R., Williams J. H., Holgate S. T.Subepithelial fibrosis in the bronchi of asthmatics. Lancet11989520524|
|463.||Altraja A., Laitinen A., Virtanen I., Kampe M., Simonsson B. G., Karlsson S. E., Hakansson L., Venge P., Sillastu H., Laitinen L. A.Expression of laminins in the airways in various types of asthmatic patients: a morphometric study. Am. J. Respir. Cell Mol. Biol.151996482488|
|464.||Saetta M., Maestrelli P., Di Stefano A., De Marzo N., Milani G. F., Pivirotto F., Mapp C. E., Fabbri L. M.Effect of cessation of exposure to toluene diisocyanate (TDI) on bronchial mucosa of subjects with TDI-induced asthma. Am. Rev. Respir. Dis.1451992169174|
|465.||Chetta A., Foresi A., Del Donno M., Bertorelli G., Pesci A., Olivieri D.Airways remodeling is a distinctive feature of asthma, and is related to severity of disease. Chest1111997852857|
|466.||Chakir J., Laviolette M., Boutet M., Laliberte R., Dube J., Boulet L. P.Lower airways remodeling in nonasthmatic subjects with allergic rhinitis. Lab. Invest.751996735744|
|467.||Ollerenshaw S. L., Woolcock A. J.Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am. Rev. Respir. Dis.1451992922927|
|468.||Battegay E. J.Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med.731995333346|
|469.||Kuwano K., Bosken C. H., Pare P. D., Bai T. R., Wiggs B. R., Hogg J. C.Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis.148199312201225|
|470.||Li X., Wilson J. W.Increased vascularity of the bronchial mucosa in mild asthma. Am. J. Respir. Crit. Care Med.1561997229233|
|471.||Laitinen L. A., Laitinen A., Widdicombe J.Effects of inflammatory and other mediators on airway vascular beds. Am. Rev. Respir. Dis.1351987S67S70|
|472.||Beck L., D'Amore P.Vascular development: cellular and molecular regulation. FASEB J.111997365373|
|473.||Brown L. F., Detmar M., Claffey K., Nagy J. A., Feng D., Dvorak A. M., Dvorak H. F.Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. J. Histochem. Cytochem.791997233269|
|474.||Nauck M., Roth M., Tamm M., Eickelberg O., Wieland H., Stulz P., Perruchoud A. P.Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am. J. Respir. Cell Mol. Biol.161997398406|
|475.||Raghow R.The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J.81994823831|
|476.||McGowan S. E.Extracellular matrix and the regulation of lung development and repair. FASEB J.6199228952904|
|477.||Goldring K., Warner J. A.Cell matrix interactions in asthma. Clin. Exp. Allergy2719972227|
|478.||van der Rest M., Garrone R.Collagen family of proteins. FASEB J.5199128142823|
|479.||Wilson J., Li X.The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin. Exp. Allergy271997363371|
|480.||Laitinen A., Altraja A., Kampe M., Linden M., Virtanen I., Laitinen L. A.Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am. J. Respir. Crit. Care Med.1561997951958|
|481.||Bousquet J., Lacoste J. Y., Chanez P., Vic P., Godard P., Michel F. B.Bronchial elastic fibers in normal subjects and asthmatic patients. Am. J. Respir. Crit. Care Med.153199616481654|
|482.||Godfrey R. W., Lorimer S., Majumdar S., Adelroth E., Johnston P. W., Rogers A. V., Johansson S. A., Jeffery P. K.Airway and lung elastic fibre is not reduced in asthma nor in asthmatics following corticosteroid treatment. Eur. Respir. J.81995922927|
|483.||Hardingham T. E., Fosang A. J.Proteoglycans: many forms and many functions. FASEB J.61992861870|
|484.||Laurent T. C., Laurent U. B., Fraser J. R.The structure and function of hyaluronan: an overview. Immunol. Cell Biol.741996A1A7|
|485.||Hamann K. J., Dowling T. L., Neeley S. P., Grant J. A., Leff A. R.Hyaluronic acid enhances cell proliferation during eosinopoiesis through the CD44 surface antigen. J. Immunol.154199540734080|
|486.||Mosher D., Sottile J., Wu C., McDonald J.Assembly of extracellular matrix. Curr. Opin. Cell Biol.41992810818|
|487.||Matrisian L. M.The matrix-degrading metalloproteinases. Bioessays141992455463|
|488.||O'Connor C. M., FitzGerald M. X.Matrix metalloproteases and lung disease. Thorax491994602609|
|489.||Vignola A. M., Bonanno A., Mirabella A., Riccobono L., Mirabella F., Profita M., Bellia V., Bousquet J., Bonsignore G.Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. Am. J. Respir. Crit. Care Med.1571998505511|
|490.||Messner J., Peters G., Bennet W.Causes of death and pathologic findings ion 304 cases of bronchial asthma. Dis. Chest381960616624|
|491.||Taipale J., Keski-Oja J.Growth factors in the extracellular matrix. FASEB J.1119975159|
|492.||Border W., Noble N.Transforming growth factor β in tissue fibrosis. N. Engl. J. Med.331199412861292|
|493.||Magnan A., Frachon I., Rain B., Peuchmaur M., Monti G., Lenot B., Fattal M., Simmoneau G., Galanaud P., Emile D.Transforming growth factor β in normal human lung: preferential location in bronchial epithelial cells. Thorax491994789792|
|494.||Ross R.Platelet-derived growth factor. Lancet1198911791182|
|495.||Heldin C. H.Structural and functional studies on platelet- derived growth factor. EMBO J.11199242514259|
|496.||Grant M. B., Khaw P. T., Schultz G. S., Adams J. L., Shimizu R. W.Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis. Invest. Ophthalmol. Vis. Sci.33199232923301|
|497.||Kumar R., Velan G., O'Grady R.Epidermal growth factor-like activity in bronchoalveolar lavage fluid in experimental silicosis. Growth Factors101994163170|
|498.||Vignola, A., P. Chanez, G. Chiappara, A. Merendino, E. Pace, A. Rizzo, A. la Rocca, V. Bellia, G. Bonsignore, and J. Bousquet. 1997. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. (In press)|
|499.||Aubert J. D., Dalal B. I., Bai T. R., Roberts C. R., Hayashi S., Hogg J. C.Transforming growth factor beta 1 gene expression in human airways. Thorax491994225232|
|500.||Hoshino M., Nakamura Y., Sim J.Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax5319982128|
|501.||Magnan A., Retornaz F., Tsicopoulos A., Brisse J., Van Pee, Gosset P., Chamlian A., Tonnel A., Vervloet D.Altered compartmentalization of transforming growth factor-β in asthmatic airways. Clin. Exp. Allergy271997389395|
|502.||Redington A. E., Madden J., Frew A. J., Djukanovic R., Roche W. R., Holgate S. T., Howarth P. H.Transforming growth factor-beta 1 in asthma: measurement in bronchoalveolar lavage fluid. Am. J. Respir. Crit. Care Med.1561997642647|
|503.||Minshall E. M., Leung D. Y., Martin R. J., Song Y. L., Cameron L., Ernst P., Hamid Q.Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol.171997326333|
|504.||Chanez P., Vignola M., Steinger R., Vic P., Michel F., Bousquet J.Platelet-derived growth factor in asthma. Allergy501995878883|
|505.||Aubert J. D., Hayashi S., Hards J., Bai T. R., Pare P. D., Hogg J. C.Platelet-derived growth factor and its receptor in lungs from patients with asthma and chronic airflow obstruction. Am. J. Physiol.2661994L655L663|
|506.||Ohno K., Ammann P., Fasciati R., Maier P.Transforming growth factor beta 1 preferentially induces apoptotic cell death in rat hepatocytes cultured under pericentral-equivalent conditions. Toxicol. Appl. Pharmacol.1321995227236|
|507.||Lama, M. 1990. Pulmonary fibrosis: human and experimental disease. In M. Rojkind, editor. Connective Tissue in Health and Disease. CRC Press, Boca Raton, FL. 123–188.|
|508.||Brown P. J., Greville H. W., Finucane K. E.Asthma and irreversible airflow obstruction. Thorax391984131136|
|509.||Greenough A., Loftus B. G., Pool J., Price J. F.Abnormalities of lung mechanics in young asthmatic children. Thorax421987500505|
|510.||Connolly M. J., Avery A. J., Walters E. H., Hendrick D. J.The relationship between bronchial responsiveness to methacholine and bronchial responsiveness to histamine in asthmatic subjects. Pulm. Pharmacol.119885358|
|511.||Boulet L. P., Turcotte H., Brochu A.Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest105199410241031|
|512.||Hudon C., Turcotte H., Laviolette M., Carrier G., Boulet L. P.Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Ann. Allergy Asthma Immunol.781997195202|
|513.||Cade J., Pain M.Pulmonary function during clinical remission of asthma: how reversible is asthma ? Aust. N.Z. J. Med.31973545551|
|514.||Ferguson A. C.Persisting airway obstruction in asymptomatic children with asthma with normal peak expiratory flow rates. J. Allergy Clin. Immunol.8219881922|
|515.||Kelly W. J., Hudson I., Raven J., Phelan P. D., Pain M. C., Olinsky A.Childhood asthma and adult lung function. Am. Rev. Respir. Dis.13819882630|
|516.||Blackhall M.Ventilatory function in subjects with childhood asthma that have become symptom free. Arch. Dis. Child.451970363366|
|517.||Wagner E. M., Liu M. C., Weinmann G. G., Permutt S., Bleecker E. R.Peripheral lung resistance in normal and asthmatic subjects. Am. Rev. Respir. Dis.1411990584588|
|518.||van Essen-Zandvliet E. E., Hughes M. D., Waalkens H. J., Duiverman E. J., Kerrebijn K. F.Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch Chronic Nonspecific Lung Disease Study Group. Eur. Respir. J.719946368|
|519.||Peat J. K., Woolcock A. J., Cullen K.Rate of decline of lung function in subjects with asthma. Eur. J. Respir. Dis.701987171179|
|520.||Lange P., Parner J., Vestbo J., Schnohr P., Jensen G.A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med.339199811941200|
|521.||Panhuysen C. I., Vonk J. M., Koeter G. H., Schouten J. P., van Altena R., Bleecker E. R., Postma D. S.Adult patients may outgrow their asthma: a 25-year follow-up study. Am. J. Respir. Crit. Care Med.155199712671272|
|522.||Burrows B., Halonen M., Lebowitz M. D., Knudson R. J., Barbee R. A.The relationship of serum immunoglobulin E, allergy skin tests, and smoking to respiratory disorders. J. Allergy Clin. Immunol.701982199204|
|523.||Schachter E. N., Doyle C. A., Beck G. J.A prospective study of asthma in a rural community. Chest851984623630|
|524.||Van Schayck C. P., Dompeling E., Van Herwaarden C. L., Wever A. M., Van Weel C.Interacting effects of atopy and bronchial hyperresponsiveness on the annual decline in lung function and the exacerbation rate in asthma. Am. Rev. Respir. Dis.144199112971301|
|525.||Almind M., Viskum K., Evald T., Dirksen A., Kok-Jensen A.A seven-year follow-up study of 343 adults with bronchial asthma. Dan. Med. Bull.391992561565|
|526.||Ulrik C. S., Backer V., Dirksen A.A 10 year follow up of 180 adults with bronchial asthma: factors important for the decline in lung function. Thorax4719921418|
|527.||van Schayck C. P., Folgering H., den Otter J. J., Tirimanna P., van Weel C.Does the continuous use of bronchodilators mask the progression of asthma or chronic bronchitis? Fam. Pract.91992397404|
|528.||Braman S. S., Kaemmerlen J. T., Davis S. M.Asthma in the elderly: a comparison between patients with recently acquired and long-standing disease. Am. Rev. Respir. Dis.1431991336340|
|529.||Burrows B., Barbee R. A., Cline M. G., Knudson R. J., Lebowitz M. D.Characteristics of asthma among elderly adults in a sample of the general population. Chest1001991935942|
|530.||Connolly M. J., Crowley J. J., Charan N. B., Nielson C. P., Vestal R. E.Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest1081995401406|
|531.||Jaakkola M. S., Jaakkola J. J., Ernst P., Becklake M. R.Respiratory symptoms in young adults should not be overlooked. Am. Rev. Respir. Dis.1471993359366|
|532.||Vergnenegre A., Antonini M. T., Bonnaud F., Melloni B., Mignonat G., Bousquet J.Comparison between late onset and childhood asthma. Allergol. Immunopathol. Madr.201992190196|
|533.||Ulrik C. S., Backer V., Dirksen A.Mortality and decline in lung function in 213 adults with bronchial asthma: a ten-year follow up. J. Asthma2919922938|
|534.||Blanc P. D., Jones M., Besson C., Katz P., Yelin E.Work disability among adults with asthma. Chest104199313711377|
|535.||Dompeling E., van Schayck C. P., Molema J., Folgering H., van Grunsven P. M., van Weel C.Inhaled beclomethasone improves the course of asthma and COPD [see comments]. Eur. Respir. J.51992945952|
|536.||Dompeling E., van Schayck C. P., van Grunsven P. M., van Herwaarden C. L., Akkermans R., Molema J., Folgering H., van Weel C.Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann. Intern. Med.1181993770778|
|537.||van Essen-Zandvliet E. E., Hughes M. D., Waalkens H. J., Duiverman E. J., Pocock S. J., Kerrebijn K. F.Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma: The Dutch Chronic Non-specific Lung Disease Study Group. Am. Rev. Respir. Dis.1461992547554|
|538.||Kerstjens H. A., Overbeek S. E., Schouten J. P., Brand P. L., Postma D. S.Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment: Dutch Chronic Nonspecific Lung Disease Study Group. Eur. Respir. J.61993868876|
|539.||Cade J.Lung mechanics during provocation of asthma. Clin. Sci.401971381386|
|540.||Colebatch H., Finucane K., Smith M.Pulmonary conductance and elastic recoil in asthma and emphysema. J. Appl. Physiol.341973143153|
|541.||McCarthy D. S., Sigurdson M.Lung elastic recoil and reduced airflow in clinically stable asthma. Thorax351980298302|
|542.||Woolcock A., Read J.The static elastic properties of the lung in asthma. Am. Rev. Respir. Dis.981968788794|
|543.||Zapletal A., Desmond K. J., Demizio D., Coates A. L.Lung recoil and the determination of airflow limitation in cystic fibrosis and asthma. Pediatr. Pulmonol.1519931318|
|544.||Neeld D. A., Goodman L. R., Gurney J. W., Greenberger P. A., Fink J. N.Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am. Rev. Respir. Dis.142199012001205|
|545.||Grenier P., Mourey-Gerosa I., Benali K., Brauner M. W., Leung A. N., Lenoir S., Cordeau M. P., Mazoyer B.Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter- and intraobserver variability. Eur. Radiol61996199206|
|546.||Paganin F., Seneterre E., Chanez P., Daures J. P., Bruel J. M., Michel F. B., Bousquet J.Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am. J. Respir. Crit. Care Med.1531996110114|
|547.||Royle X.X-ray appearances in asthma. B.M.J.i1952577580|
|548.||Biernacki W., Redpath A., Best J., MacNee W.Measurement of CT lung density in patients with chronic asthma. Eur. Respir. J.10199724552459|
|549.||Park C. S., Muller N. L., Worthy S. A., Kim J. S., Awadh N., Fitzgerald M.Airway obstruction in asthmatic and healthy individuals: inspiratory and expiratory thin-section CT findings. Radiology2031997361367|
|550.||Paganin F., Jaffuel D., Bousquet J.Significance of emphysema observed on computed tomography scan in asthma [editorial; comment]. Eur. Respir. J.10199724462448|
|551.||Mclean A., Sproule M., Cowan M., Thompson N.High resolution computed tomography in asthma. Thorax531998308314|
|552.||Laitinen L.A., Laitinen A.Remodeling of asthmatic airways by glucocorticosteroids. J. Allergy Clin. Immunol.971996153158|
|553.||Jeffery P. K., Godfrey R. W., Adelroth E., Nelson F., Rogers A., Johansson S. A.Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am. Rev. Respir. Dis.1451992890899|
|554.||Lundgren R., Soderberg M., Horstedt P., Stenling R.Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur. Respir. J.11988883889|
|555.||Saetta M., Maestrelli P., Turato G., Mapp C. E., Milani G., Pivirotto F., Fabbri L. M., Di Stefano A.Airway wall remodeling after cessation of exposure to isocyanates in sensitized asthmatic subjects. Am. J. Respir. Crit. Care Med.1511995489494|
|556.||Olivieri D., Chetta A., Del Donno M., Bertorelli G., Casalani A., Pesci A., Testi R., Foresi A.Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am. J. Respir. Crit. Care Med.155199718641871|
|557.||Padrid P. A., Cozzi P., Leff A. R.Cyclosporine A inhibits airway reactivity and remodeling after chronic antigen challenge in cats. Am. J. Respir. Crit. Care Med.154199618121818|
|558.||Agertoft L., Pedersen S.Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir. Med.881994373381|
|559.||Haahtela T., Jarvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Selroos O., Sovijarvi A., Stenius-Aarniala B., Svahn T., Tammivara R., Laitinen L.Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N. Engl. J. Med.3311994700705|
|560.||Selroos O., Pietinalho A., Lofroos A. B., Riska H.Effect of early vs late intervention with inhaled corticosteroids in asthma [see comments]. Chest108199512281234|
|561.||Overbeek S. E., Kerstjens H. A., Bogaard J. M., Mulder P. G., Postma D. S.Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest11019963541|